# Índice Maestro — Repositorio Ganglio cN+ → ypN0 (Sergio Cervera)

**Total de entradas:** 376
**Fecha de compilación:** 2026-05-12

> Listado completo de artículos por carpeta. Click sobre el título para abrir el archivo Markdown con metadatos, abstract y (cuando disponible) full-text. DOIs enlazan al artículo original.

## Estadísticas por carpeta

| Carpeta | N |
|---------|--:|
|  | 1 |
| 01 — Revisiones sistemáticas y meta-análisis | 23 |
| 02 — Ensayos clínicos (pivotales y registros) | 54 |
| 03 — Cáncer de mama (axila, general) | 20 |
| 04 — Otros tumores con conversión nodal | 71 |
| 05 — Técnicas quirúrgicas (TAD, SLNB) | 32 |
| 06 — Imagen, marcaje y predicción | 26 |
| 07 — Anatomía patológica | 12 |
| 08 — Guías clínicas | 28 |
| 09 — Radioterapia adaptada post-NAC | 8 |
| 10 — Pronóstico y supervivencia | 7 |
| _amstar2_toolkit | 36 |
| _excluded_after_triage_2026-05-14 | 10 |
| predictor_ypN0 | 48 |
| **TOTAL** | **376** |

## 

- **----** · [Resumen ejecutivo GENERAL — Algoritmo clínico paso a paso: paciente cN+ con NAC](RESUMEN_00_GENERAL_algoritmo_clinico.md) — *?* · 

## 01 — Revisiones sistemáticas y meta-análisis

- **2026** · [Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.](01_revisiones_metaanalisis/2026_Abdulla_Meta-analisis_Ann-Surg-Oncol.md) — *Abdulla Hussain A* · PMID 41545613 · [DOI](https://doi.org/10.1245/s10434-025-19070-2)
- **2025** · [Use of superparamagnetic iron oxide for sentinel lymph node detection following neoadjuvant systemic therapy. A systematic review and meta-analysis.](01_revisiones_metaanalisis/2025_Boland_Meta-analisis_Eur-J-Surg-Oncol.md) — *Boland M R* · PMID 40009931 · [DOI](https://doi.org/10.1016/j.ejso.2025.109684)
- **2025** · [Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.](01_revisiones_metaanalisis/2025_Ding_Meta-analisis_J-Cancer-Res-Ther.md) — *Ding Fangjie* · PMID 40317154 · [DOI](https://doi.org/10.4103/jcrt.jcrt_1279_24)
- **2025** · [Different strategies in de-escalation of axillary surgery in node-positive breast cancer following neoadjuvant treatment: a systematic review and meta-analysis of long-term outcomes.](01_revisiones_metaanalisis/2025_Man_Meta-analisis_Breast-Cancer.md) — *Man Vivian* · PMID 40186790 · PMC12174186 · [DOI](https://doi.org/10.1007/s12282-025-01692-9)
- **2025** · [Long-Term Survival of Node-Positive Breast Cancer with Complete Nodal Response to Neoadjuvant Chemotherapy Treated with Sentinel Lymph Node Biopsy Alone: A Meta-Analysis.](01_revisiones_metaanalisis/2025_Wang_Meta-analisis_Oncology.md) — *Wang Zhanwei* · PMID 39899993 · [DOI](https://doi.org/10.1159/000543662)
- **2024** · [Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement](01_revisiones_metaanalisis/2024_deWild_TAD-systematic-review_BJS.md) — *Sabine R de Wild* · PMID 38531689 · PMC10965400 · [DOI](https://doi.org/10.1093/bjs/znae071)
- **2024** · [Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2- Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis](01_revisiones_metaanalisis/2024_Vasigh_NET-vs-NAC-cN-positive_Breast-J.md) — *Mahtab Vasigh* · PMID 39742366 · PMC11315960 · [DOI](https://doi.org/10.1155/2024/8866756)
- **2022** · [Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data.](01_revisiones_metaanalisis/2022_Lin_Meta-analisis_Ann-Surg-Oncol.md) — *Lin Shi-Qian* · PMID 35018590 · [DOI](https://doi.org/10.1245/s10434-021-11297-z)
- **2022** · [Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.](01_revisiones_metaanalisis/2022_Song_Meta-analisis_Cancer-Med.md) — *Song Yu-Xin* · PMID 35502768 · PMC9678111 · [DOI](https://doi.org/10.1002/cam4.4769)
- **2022** · [The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review.](01_revisiones_metaanalisis/2022_Vxe1zquez_Revision-sistematica_Clin-Transl-Oncol.md) — *V&#xe1;zquez Juan C* · PMID 36153763 · [DOI](https://doi.org/10.1007/s12094-022-02953-1)
- **2021** · [Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,5](01_revisiones_metaanalisis/2021_Cao_Meta-analisis_Breast.md) — *Cao Siyang* · PMID 34325383 · PMC8334738 · [DOI](https://doi.org/10.1016/j.breast.2021.07.015)
- **2021** · [Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis](01_revisiones_metaanalisis/2021_Samiei_Axillary-pCR-by-subtype_JAMA-Surg.md) — *Sanaz Samiei* · PMID 33881478 · PMC8060891 · [DOI](https://doi.org/10.1001/jamasurg.2021.0891)
- **2019** · [Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.](01_revisiones_metaanalisis/2019_Simons_Meta-analisis_Ann-Surg.md) — *Simons Janine M* · PMID 30312200 · PMC6369968 · [DOI](https://doi.org/10.1097/SLA.0000000000003075)
- **2018** · [Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review.](01_revisiones_metaanalisis/2018_Krug_Revision-sistematica_Strahlenther-Onkol.md) — *Krug David* · PMID 29383405 · [DOI](https://doi.org/10.1007/s00066-018-1270-x)
- **2018** · [Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer.](01_revisiones_metaanalisis/2018_Tee_Meta-analisis_Br-J-Surg.md) — *Tee S R* · PMID 30311642 · [DOI](https://doi.org/10.1002/bjs.10986)
- **2016** · [Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis i](01_revisiones_metaanalisis/2016_El-Hage-Chehade_Meta-analisis_Am-J-Surg.md) — *El Hage Chehade Hiba* · PMID 27671032 · [DOI](https://doi.org/10.1016/j.amjsurg.2016.07.018)
- **2015** · [Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and meta-analysis.](01_revisiones_metaanalisis/2015_Mocellin_Meta-analisis_Int-J-Cancer.md) — *Mocellin Simone* · PMID 26084763 · [DOI](https://doi.org/10.1002/ijc.29644)
- **2015** · [The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis.](01_revisiones_metaanalisis/2015_van-Nijnatten_Meta-analisis_Eur-J-Surg-Oncol.md) — *van Nijnatten T J A* · PMID 26329781 · [DOI](https://doi.org/10.1016/j.ejso.2015.07.020)
- **2014** · [Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.](01_revisiones_metaanalisis/2014_Schipper_Revision-sistematica_Eur-J-Radiol.md) — *Schipper R J* · PMID 25458227 · [DOI](https://doi.org/10.1016/j.ejrad.2014.09.020)
- **2009** · [Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis.](01_revisiones_metaanalisis/2009_Kelly_Revision-sistematica_Acad-Radiol.md) — *Kelly Aine M* · PMID 19345896 · [DOI](https://doi.org/10.1016/j.acra.2009.01.026)
- **2009** · [Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review.](01_revisiones_metaanalisis/2009_van-Deurzen_Revision-sistematica_Eur-J-Cancer.md) — *van Deurzen Carolien H M* · PMID 19716287 · [DOI](https://doi.org/10.1016/j.ejca.2009.08.001)
- **2006** · [Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.](01_revisiones_metaanalisis/2006_Xing_Meta-analisis_Br-J-Surg.md) — *Xing Y* · PMID 16329089 · [DOI](https://doi.org/10.1002/bjs.5209)
- **----** · [The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis](01_revisiones_metaanalisis/2021_Swarnkar_MLNB-TAD-pooled_Cancers.md) — *Parinita K Swarnkar* · PMID 33810544 · PMC8037051 · [DOI](https://doi.org/10.3390/cancers13071539)

## 02 — Ensayos clínicos (pivotales y registros)

- **2026** · [Locoregional and symptomatic response to neoadjuvant dual HER2 blockade with chemotherapy in HER2-positive breast cancer: a pilot study.](02_ensayos_clinicos/2026_Chowdhary_cN2cN3-NAC-axilla_AnticancerDrugs.md) — *Chowdhary GS* · PMID 41176781 · [DOI](https://doi.org/10.1097/CAD.0000000000001780)
- **2026** · [Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.](02_ensayos_clinicos/2026_Kuemmel_TNBC-NAC-axillary_AnnSurgOnco.md) — *Kuemmel S* · PMID 41739398 · [DOI](https://doi.org/10.1245/s10434-026-19121-2)
- **2025** · [Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) ](02_ensayos_clinicos/2025_Banys-Paluchowski_TAD-NAC-institutional_BreaCancRes.md) — *Banys-Paluchowski M* · PMID 39976867 · [DOI](https://doi.org/10.1007/s10549-025-07635-4)
- **2025** · [De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer (NEOSENTITURK MF-1803)](02_ensayos_clinicos/2025_Cabioglu_De-escalation-NEOSENTITURK_JAMA-Surg.md) — *Neslihan Cabioglu* · PMID 39745737 · PMC11904723 · [DOI](https://doi.org/10.1001/jamasurg.2024.5913)
- **2025** · [Surgical MArker Localization OR clip and wire application for targeted axillary dissection in node-positive breast cancer patients - Results from the randomized superiority MALLORCA-trial.](02_ensayos_clinicos/2025_Elfgen_TAD-NAC-institutional_EurJSurg.md) — *Elfgen C* · PMID 40582174 · [DOI](https://doi.org/10.1016/j.ejso.2025.110266)
- **2025** · [Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.](02_ensayos_clinicos/2025_Geyer_HER2-NAC-axillary_NEnglJ.md) — *Geyer CE* · PMID 39813643 · [DOI](https://doi.org/10.1056/NEJMoa2406070)
- **2025** · [Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial](02_ensayos_clinicos/2025_Kuerer_Selective-elimination-breast-surgery_JAMA-Oncol.md) — *Henry M Kuerer* · PMID 40152443 · PMC11953967 · [DOI](https://doi.org/10.1001/jamaoncol.2025.0207)
- **2025** · [Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)](02_ensayos_clinicos/2025_Mamounas_NSABP-B51_NEJM.md) — *Eleftherios P Mamounas* · PMID 40466065 · PMC12269788 · [DOI](https://doi.org/10.1056/NEJMoa2414859)
- **2025** · [Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY](02_ensayos_clinicos/2025_Mukhtar_cN2cN3-NAC-axilla_AnnSurgOnco.md) — *Mukhtar RA* · PMID 40705266 · PMC12494636 · [DOI](https://doi.org/10.1245/s10434-025-17862-0)
- **2025** · [Effects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer: The randomized controlled BENEFIT trial.](02_ensayos_clinicos/2025_Schmidt_NAC-axila_J-Sport-Health-Sci.md) — *Schmidt Martina E* · PMID 40447136 · PMC12395146 · [DOI](https://doi.org/10.1016/j.jshs.2025.101064)
- **2025** · [Nomogram for predicting axillary pathologic complete response after neoadjuvant systemic therapy in HER2 positive and triple negative breast cancer.](02_ensayos_clinicos/2025_Shi_HER2-NAC-axillary_JCancer.md) — *Shi Z* · PMID 41049013 · PMC12491205 · [DOI](https://doi.org/10.7150/jca.118908)
- **2024** · [Nodal Response and Survival After Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive Breast Cancer: 20-Year Experience from a Single Institution.](02_ensayos_clinicos/2024_An_HER2-NAC-axillary_AnnSurgOnco.md) — *An SJ* · PMID 39154153 · PMC11560637 · [DOI](https://doi.org/10.1245/s10434-024-16059-1)
- **2024** · [Pathologic Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Postpartum High-Risk Basal-Type Breast Cancer.](02_ensayos_clinicos/2024_Jiang_TNBC-NAC-axillary_Cureus.md) — *Jiang H* · PMID 39006626 · PMC11246238 · [DOI](https://doi.org/10.7759/cureus.62338)
- **2024** · [RISAS Sub-Análisis: PET/CT Pre-NAC + Subtipo Molecular como Predictores de ypN0 Axilar](02_ensayos_clinicos/2024_vanAmstel_RISAS-PETCT-predictor-ypN0_BJS.md) — *van Amstel FJG* · PMID 39302345 · PMC11414043 · [DOI](https://doi.org/10.1093/bjs/znae203)
- **2024** · [Diagnostic accuracy of sentinel lymph node biopsy and wire localized clipped node biopsy after neoadjuvant chemotherapy in node-positive breast cancer.](02_ensayos_clinicos/2024_Wang_TAD-NAC-institutional_SurgToday.md) — *Wang X* · PMID 39725764 · [DOI](https://doi.org/10.1007/s00595-024-02981-0)
- **2023** · [The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Ne](02_ensayos_clinicos/2023_Blumencranz_HER2-NAC-axillary_AnnSurgOnco.md) — *Blumencranz P* · PMID 37658272 · PMC10625953 · [DOI](https://doi.org/10.1245/s10434-023-14027-9)
- **2023** · [Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.](02_ensayos_clinicos/2023_Takahashi_TNBC-NAC-axillary_JamaNetwOpen.md) — *Takahashi M* · PMID 37966841 · PMC10652156 · [DOI](https://doi.org/10.1001/jamanetworkopen.2023.42107)
- **2023** · [Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.](02_ensayos_clinicos/2023_Woodfin_TNBC-NAC-axillary_AnnSurgOnco.md) — *Woodfin AA* · PMID 37973647 · [DOI](https://doi.org/10.1245/s10434-023-14541-w)
- **2023** · [Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in Ch](02_ensayos_clinicos/2023_Yang_TAD-NAC-institutional_WorlJSurg.md) — *Yang X* · PMID 37480099 · PMC10360322 · [DOI](https://doi.org/10.1186/s12957-023-03120-8)
- **2022** · [De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): WSG-ADAPT-TN Trial](02_ensayos_clinicos/2022_Gluz_WSG-ADAPT-TN_CCR.md) — *Oleg Gluz* · PMID 35797219 · [DOI](https://doi.org/10.1158/1078-0432.CCR-22-0482)
- **2022** · [Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer.](02_ensayos_clinicos/2022_Ladak_HER2-NAC-axillary_CanJSurg.md) — *Ladak F* · PMID 35135785 · PMC8834246 · [DOI](https://doi.org/10.1503/cjs.012920)
- **2022** · [Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery](02_ensayos_clinicos/2022_Pfob_Vacuum-biopsy-ypT0-ypN0_J-Clin-Oncol.md) — *Pfob Andr&#xe9;* · PMID 35108029 · [DOI](https://doi.org/10.1200/JCO.21.02439)
- **2022** · [Trends in Sentinel Lymph Node Biopsies in Patients With Inflammatory Breast Cancer in the US.](02_ensayos_clinicos/2022_Sosa_IBC-neoadjuvant-axilla_JamaNetwOpen.md) — *Sosa A* · PMID 35147686 · PMC8837909 · [DOI](https://doi.org/10.1001/jamanetworkopen.2021.48021)
- **2022** · [Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers.](02_ensayos_clinicos/2022_Yang_IBC-neoadjuvant-axilla_BreaCancRes.md) — *Yang J* · PMID 35129717 · [DOI](https://doi.org/10.1007/s10549-022-06539-x)
- **2021** · [Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.](02_ensayos_clinicos/2021_Chen_HER2-NAC-axillary_FutureOncol.md) — *Chen P* · PMID 33878939 · [DOI](https://doi.org/10.2217/fon-2020-1231)
- **2021** · [Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.](02_ensayos_clinicos/2021_Foldi_HER2-NAC-axillary_CurrTreaOpti.md) — *Foldi J* · PMID 34213636 · [DOI](https://doi.org/10.1007/s11864-021-00879-4)
- **2021** · [Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.](02_ensayos_clinicos/2021_Mamounas_HER2-NAC-axillary_AnnOncol.md) — *Mamounas EP* · PMID 33932503 · [DOI](https://doi.org/10.1016/j.annonc.2021.04.011)
- **2021** · [Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)](02_ensayos_clinicos/2021_Sharma_NeoSTOP_Clin-Cancer-Res.md) — *Priyanka Sharma* · PMID 33208340 · PMC7887017 · [DOI](https://doi.org/10.1158/1078-0432.CCR-20-3646)
- **2021** · [The importance of sentinel lymph node biopsy following neoadjuvant chemotherapy in patients with breast cancer: prospective multicentre trial.](02_ensayos_clinicos/2021_xdateckxfd_IBC-neoadjuvant-axilla_RozhlChir.md) — *&#x17d;ateck&#xfd; J* · PMID 34465116 · [DOI](https://doi.org/10.33699/PIS.2021.100.6.271-277)
- **2020** · [Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal ](02_ensayos_clinicos/2020_Conte_HER2-NAC-axillary_Cancer.md) — *Conte P* · PMID 32286687 · PMC7317721 · [DOI](https://doi.org/10.1002/cncr.32873)
- **2020** · [Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.](02_ensayos_clinicos/2020_Denduluri_HER2-NAC-axillary_JClinOnco.md) — *Denduluri N* · PMID 33079579 · [DOI](https://doi.org/10.1200/JCO.20.02510)
- **2020** · [Axillary management after neoadjuvant treatment.](02_ensayos_clinicos/2020_Montagna_cN2cN3-NAC-axilla_MinervaChir.md) — *Montagna G* · PMID 33345526 · [DOI](https://doi.org/10.23736/S0026-4733.20.08600-9)
- **2020** · [Local management after neoadjuvant treatment for breast cancer.](02_ensayos_clinicos/2020_Sakai_cN2cN3-NAC-axilla_ChinClinOnco.md) — *Sakai T* · PMID 32576022 · [DOI](https://doi.org/10.21037/cco-20-164)
- **2020** · [Seguridad Oncológica de SLNB Sola Tras NAC en ypN0 (McGill/Jewish General)](02_ensayos_clinicos/2020_Wong-Boileau_SLNB-sola-ypN0_Ann-Surg-Oncol.md) — *Wong SM* · PMID 33095362 · [DOI](https://doi.org/10.1245/s10434-020-09211-0)
- **2019** · [Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial](02_ensayos_clinicos/2019_Haffty_Radioterapia-NAC_Int-J-Radiat-Oncol-Biol-Phys.md) — *Haffty Bruce G* · PMID 31085287 · PMC6699883 · [DOI](https://doi.org/10.1016/j.ijrobp.2019.04.038)
- **2019** · [Axillary Pathologic Complete Response in Inflammatory Breast Cancer Patients: Implications for SLNB?](02_ensayos_clinicos/2019_Imeokparia_Clip-marker_Ann-Surg-Oncol.md) — *Imeokparia Folasade O* · PMID 31342381 · [DOI](https://doi.org/10.1245/s10434-019-07597-0)
- **2018** · [Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.](02_ensayos_clinicos/2018_Barron_HER2-NAC-axillary_JAMASurg.md) — *Barron AU* · PMID 30193375 · PMC6583006 · [DOI](https://doi.org/10.1001/jamasurg.2018.2696)
- **2018** · [Reducción del 82% de Linfadenectomías Axilares Combinando PET/CT pre-NAC + MARI post-NAC](02_ensayos_clinicos/2018_vanDerNoordaa_PETCT-MARI_82-reduccion-ALND_Ann-Surg-Oncol.md) — *van der Noordaa MEM* · PMID 29511992 · [DOI](https://doi.org/10.1245/s10434-018-6404-y)
- **2018** · [Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.](02_ensayos_clinicos/2018_von_HER2-NAC-axillary_NEnglJ.md) — *von Minckwitz G* · PMID 30516102 · [DOI](https://doi.org/10.1056/NEJMoa1814017)
- **2017** · [Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial](02_ensayos_clinicos/2017_deBoniface_SENOMAC_BMC-Cancer.md) — *Jana de Boniface* · PMID 28549453 · PMC5446737 · [DOI](https://doi.org/10.1186/s12885-017-3361-y)
- **2017** · [Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast&#xa0;Cancer.](02_ensayos_clinicos/2017_DeSnyder_IBC-neoadjuvant-axilla_ClinBreaCanc.md) — *DeSnyder SM* · PMID 28755879 · [DOI](https://doi.org/10.1016/j.clbc.2017.06.014)
- **2017** · [RISAS — Protocolo del Ensayo Prospectivo Multicéntrico Holandés (MARI + SLNB combinados)](02_ensayos_clinicos/2017_vanNijnatten-Simons_RISAS-protocolo_Clin-Breast-Cancer.md) — *van Nijnatten TJA* · PMID 28487053 · [DOI](https://doi.org/10.1016/j.clbc.2017.04.006)
- **2016** · [Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.](02_ensayos_clinicos/2016_Lyman_IBC-neoadjuvant-axilla_JClinOnco.md) — *Lyman GH* · PMID 27937089 · [DOI](https://doi.org/10.1200/JCO.2016.71.0947)
- **2015** · [SN FNAC — Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer](02_ensayos_clinicos/2015_Boileau_SN-FNAC_JCO.md) — *Boileau JF* · PMID 25452445 · [DOI](https://doi.org/10.1200/JCO.2014.55.7827)
- **2015** · [MARI Procedure — Marking Axillary Lymph Nodes With Radioactive Iodine Seeds (Original)](02_ensayos_clinicos/2015_Donker_MARI_Ann-Surg.md) — *Donker M* · PMID 24743607 · [DOI](https://doi.org/10.1097/SLA.0000000000000558)
- **2014** · [Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.](02_ensayos_clinicos/2014_Lyman_IBC-neoadjuvant-axilla_JClinOnco.md) — *Lyman GH* · PMID 24663048 · [DOI](https://doi.org/10.1200/JCO.2013.54.1177)
- **2014** · [Current and future role of neoadjuvant therapy for breast cancer.](02_ensayos_clinicos/2014_Untch_IBC-neoadjuvant-axilla_Breast.md) — *Untch M* · PMID 25034931 · [DOI](https://doi.org/10.1016/j.breast.2014.06.004)
- **2013** · [ACOSOG Z1071 — Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer](02_ensayos_clinicos/2013_Boughey_ACOSOG-Z1071_JAMA.md) — *Boughey JC* · PMID 24101169 · PMC4075763 · [DOI](https://doi.org/10.1001/jama.2013.278932)
- **2013** · [Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study](02_ensayos_clinicos/2013_Kuehn_SENTINA_Lancet-Oncol.md) — *Thorsten Kuehn* · PMID 23683750 · [DOI](https://doi.org/10.1016/S1470-2045(13)70166-9)
- **2009** · [GANEA — Ganglion Sentinelle et Chimiothérapie Néoadjuvante (French Multicenter)](02_ensayos_clinicos/2009_Classe_GANEA_French_JCO.md) — *Classe JM* · PMID 19114697 · [DOI](https://doi.org/10.1200/JCO.2008.18.3228)
- **2001** · [Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer.](02_ensayos_clinicos/2001_Gradishar_cN2cN3-NAC-axilla_ClinBreaCanc.md) — *Gradishar WJ* · PMID 11970742 · [DOI](https://doi.org/10.3816/cbc.2001.s.005)
- **----** · [Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer](02_ensayos_clinicos/2022_Simons_RISAS-resultados_JAMA-Surg.md) — *Simons JM et al. (RISAS Study Group* · PMID 36069889 · PMC9453629 · [DOI](https://doi.org/10.1001/jamasurg.2022.3907)
- **----** · [Adding Neoadjuvant Immunotherapy to Chemotherapy in Non-Metastatic Triple-Negative Breast Cancer: A Propensity-Matched Cohort Study from a Tertiary Cancer Center.](02_ensayos_clinicos/2025_Al-Masri_TNBC-NAC-axillary_CancersBasel.md) — *Al-Masri M* · PMID 41463184 · PMC12730321 · [DOI](https://doi.org/10.3390/cancers17243933)
- **----** · [Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort](02_ensayos_clinicos/2025_OPBC-07-microNAC_ALND-vs-noALND_LancetOncol.md) — *OPBC-07/microNAC international collaborative group* · PMID 41449148 · PMC12883204 · [DOI](https://doi.org/10.1016/S1470-2045(25)00598-4)

## 03 — Cáncer de mama (axila, general)

- **2025** · [Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1-2 Breast Cancer: An Internally Validated PET/CT-Integrated Nomogram.](03_cancer_mama_axila/2025_Berkexfoxflu_IBC-neoadjuvant-axilla_CurrOncol.md) — *Berke&#x15f;o&#x11f;lu M* · PMID 41440195 · PMC12732181 · [DOI](https://doi.org/10.3390/curroncol32120667)
- **2025** · [Omission of axillary dissection after neoadjuvant systemic treatment in initially node-positive HER2-overexpressed and triple-negative breast cancer patients: SENATURK OTHER-NAC study.](03_cancer_mama_axila/2025_Cabxoxflu_cN2cN3-NAC-axilla_EurJSurg.md) — *Cab&#x131;o&#x11f;lu N* · PMID 40009910 · [DOI](https://doi.org/10.1016/j.ejso.2025.109642)
- **2025** · [Contemporary Trends in Axillary Surgery for ER-Positive, HER2-Negative Breast Cancer Stratified by Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, or Upfront Surgery](03_cancer_mama_axila/2025_Douglas_ER-HER2-trends-axilla_Ann-Surg-Oncol.md) — *Sasha R Douglas* · PMID 40986210 · PMC12619107 · [DOI](https://doi.org/10.1245/s10434-025-18225-5)
- **2024** · [Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.](03_cancer_mama_axila/2024_Engin_IBC-neoadjuvant-axilla_AdvExpMed.md) — *Engin A* · PMID 39287872 · [DOI](https://doi.org/10.1007/978-3-031-63657-8_26)
- **2024** · [The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Posi](03_cancer_mama_axila/2024_Wanis_IBC-neoadjuvant-axilla_AnnSurgOnco.md) — *Wanis KN* · PMID 39048903 · [DOI](https://doi.org/10.1245/s10434-024-15712-z)
- **2023** · [Outcomes of Breast-Conserving Therapy in Patients With Inflammatory Breast Cancer: A Meta-Analysis.](03_cancer_mama_axila/2023_Lai_IBC-neoadjuvant-axilla_JSurgRes.md) — *Lai HY* · PMID 37820394 · [DOI](https://doi.org/10.1016/j.jss.2023.08.047)
- **2023** · [Neoadjuvant Therapy in Nonmetastatic Breast Cancer in Kurdistan, Iraq.](03_cancer_mama_axila/2023_Namiq_cN2cN3-NAC-axilla_JcoGlobOnco.md) — *Namiq KS* · PMID 37216625 · PMC10497289 · [DOI](https://doi.org/10.1200/GO.22.00276)
- **2022** · [Regional Nodal Management After Preoperative Systemic Therapy.](03_cancer_mama_axila/2022_Singer_cN2cN3-NAC-axilla_SemiRadiOnco.md) — *Singer L* · PMID 35688521 · [DOI](https://doi.org/10.1016/j.semradonc.2022.01.003)
- **2021** · [Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.](03_cancer_mama_axila/2021_Hammond_cN2cN3-NAC-axilla_ClinBreaCanc.md) — *Hammond JB* · PMID 34462208 · [DOI](https://doi.org/10.1016/j.clbc.2021.07.006)
- **2021** · [Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management.](03_cancer_mama_axila/2021_Relation_cN2cN3-NAC-axilla_AnnSurgOnco.md) — *Relation T* · PMID 33586065 · PMC8491425 · [DOI](https://doi.org/10.1245/s10434-021-09657-w)
- **2020** · [Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.](03_cancer_mama_axila/2020_Fayanju_IBC-neoadjuvant-axilla_BreaCancRes.md) — *Fayanju OM* · PMID 31960171 · PMC7050768 · [DOI](https://doi.org/10.1007/s10549-020-05529-1)
- **2020** · [Inflammatory breast cancer associated with amyopathic dermatomyositis: a case report.](03_cancer_mama_axila/2020_Inaguma_IBC-neoadjuvant-axilla_SurgCaseRep.md) — *Inaguma G* · PMID 33175305 · PMC7658279 · [DOI](https://doi.org/10.1186/s40792-020-01066-7)
- **2017** · [Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.](03_cancer_mama_axila/2017_Gentile_cN2cN3-NAC-axilla_AnnSurgOnco.md) — *Gentile LF* · PMID 28916978 · PMC5697706 · [DOI](https://doi.org/10.1245/s10434-017-6085-y)
- **2009** · [Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer.](03_cancer_mama_axila/2009_Hidar_IBC-neoadjuvant-axilla_IntJSurg.md) — *Hidar S* · PMID 19410665 · [DOI](https://doi.org/10.1016/j.ijsu.2009.04.012)
- **2007** · [Positive and negative aspects of sentinel lymph node biopsy in breast cancer.](03_cancer_mama_axila/2007_Clark_IBC-neoadjuvant-axilla_FutureOncol.md) — *Clark SE* · PMID 17280503 · [DOI](https://doi.org/10.2217/14796694.3.1.65)
- **2007** · [Neoadjuvant systemic therapy and the surgical management of breast cancer.](03_cancer_mama_axila/2007_Waljee_IBC-neoadjuvant-axilla_SurgClinNort.md) — *Waljee JF* · PMID 17498534 · [DOI](https://doi.org/10.1016/j.suc.2007.02.004)
- **2002** · [Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.](03_cancer_mama_axila/2002_Stearns_IBC-neoadjuvant-axilla_AnnSurgOnco.md) — *Stearns V* · PMID 11923129 · [DOI](https://doi.org/10.1007/BF02573060)
- **2000** · [Locally advanced breast cancer.](03_cancer_mama_axila/2000_Sikov_IBC-neoadjuvant-axilla_CurrTreaOpti.md) — *Sikov WM* · PMID 12057165 · [DOI](https://doi.org/10.1007/s11864-000-0034-9)
- **----** · [Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment.](03_cancer_mama_axila/2020_Karanlik_IBC-neoadjuvant-axilla_BreaCareBase.md) — *Karanlik H* · PMID 34720806 · PMC8543304 · [DOI](https://doi.org/10.1159/000512202)
- **----** · [Updates in Surgical Management of the Axilla](03_cancer_mama_axila/2025_Mamtani_Surgical-management-axilla_Oncology.md) — *Anita Mamtani* · PMID 40117118 · [DOI](https://doi.org/10.46883/2025.25921035)

## 04 — Otros tumores con conversión nodal

- **2026** · [Neoadjuvant Chemoimmunotherapy Followed by Surgery for Non-Small Cell Lung Cancer: Current Evidence and Unmet Needs.](04_otros_tumores/2026_Kim_NSCLC-CheckMate-816_Eur-J-Cardiothorac-Surg.md) — *Kim HK* · PMID 42102248 · [DOI](https://doi.org/10.1093/ejcts/ezaf471)
- **2026** · [Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.](04_otros_tumores/2026_Shitara_Gastric-FLOT-nodal_ESMO-Open.md) — *Shitara K* · PMID 41747585 · PMC12955660 · [DOI](https://doi.org/10.1016/j.esmoop.2026.106090)
- **2026** · [Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.](04_otros_tumores/2026_Vulsteke_Bladder-perio-pembro_N-Engl-J-Med.md) — *Vulsteke C* · PMID 41707170 · [DOI](https://doi.org/10.1056/NEJMoa2511674)
- **2025** · [Does Extramural Vascular Invasion Predict Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer?](04_otros_tumores/2025_Bhutiani_Rectal-TNT-ypN0_Clin-Colorectal-Cancer.md) — *Bhutiani N* · PMID 40038019 · [DOI](https://doi.org/10.1016/j.clcc.2025.02.002)
- **2025** · [Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer.](04_otros_tumores/2025_Bu_Gastric-perioperative_BMC-Cancer.md) — *Bu S* · PMID 40251501 · PMC12007279 · [DOI](https://doi.org/10.1186/s12885-025-14103-1)
- **2025** · [Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.](04_otros_tumores/2025_Forde_NSCLC-CheckMate-816_N-Engl-J-Med.md) — *Forde PM* · PMID 40454642 · [DOI](https://doi.org/10.1056/NEJMoa2502931)
- **2025** · [Is less more? Revisiting elective nodal irradiation in head and neck cancer.](04_otros_tumores/2025_Haderlein_HeadNeck-induction-nodal_Strahlenther-Onkol.m.md) — *Haderlein M* · PMID 40705060 · [DOI](https://doi.org/10.1007/s00066-025-02437-5)
- **2025** · [Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non-small cell lung cancer.](04_otros_tumores/2025_Jones_NSCLC-chemo-IO-ypN0_J-Thorac-Cardiovasc-Surg.md) — *Jones D* · PMID 40684849 · [DOI](https://doi.org/10.1016/j.jtcvs.2025.07.014)
- **2025** · [Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [F]FDG PET/CT.](04_otros_tumores/2025_Li_NSCLC-chemo-IO-ypN0_Eur-Radiol.md) — *Li S* · PMID 40483295 · [DOI](https://doi.org/10.1007/s00330-025-11729-4)
- **2025** · [Lung cancer recurrence after neoadjuvant immunotherapy.](04_otros_tumores/2025_Li_NSCLC-mediastinal-downstaging_J-Thorac-Cardiovasc-Su.md) — *Li H* · PMID 40328424 · [DOI](https://doi.org/10.1016/j.jtcvs.2025.04.028)
- **2025** · [Prognostic Implications of Lymph Node Status in Non-Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Study.](04_otros_tumores/2025_Ma_NSCLC-chemo-IO-ypN0_Clin-Lung-Cancer.md) — *Ma R* · PMID 40316494 · [DOI](https://doi.org/10.1016/j.cllc.2025.04.004)
- **2025** · [Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II c](04_otros_tumores/2025_Meng_Gastric-FLOT-nodal_Front-Immunol.md) — *Meng X* · PMID 40799651 · PMC12339537 · [DOI](https://doi.org/10.3389/fimmu.2025.1638316)
- **2025** · [Performance of conventional MRI and endoscopy in assessing complete tumor response following immunotherapy-based neoadjuvant therapy for rectal cancer.](04_otros_tumores/2025_Miao_Rectal-ypN0-prognosis_Eur-J-Radiol.md) — *Miao G* · PMID 40602296 · [DOI](https://doi.org/10.1016/j.ejrad.2025.112267)
- **2025** · [MRI of the Rectum: A Decade into DISTANCE, Moving to DISTANCED.](04_otros_tumores/2025_Nougaret_Rectal-watch-wait_Radiology.md) — *Nougaret S* · PMID 39772798 · [DOI](https://doi.org/10.1148/radiol.232838)
- **2025** · [Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial](04_otros_tumores/2025_Ozkurt_Vitamin-D-pCR_World-J-Surg.md) — *Enver Özkurt* · PMID 40229998 · PMC12134193 · [DOI](https://doi.org/10.1002/wjs.12587)
- **2025** · [Impact of PD1 blockade added to neoadjuvant chemoradiotherapy on rectal cancer surgery: post-hoc analysis of the randomized POLARSTAR trial.](04_otros_tumores/2025_Pang_Rectal-ypN0-prognosis_Br-J-Surg.md) — *Pang K* · PMID 40119727 · [DOI](https://doi.org/10.1093/bjs/znaf057)
- **2025** · [Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Poo](04_otros_tumores/2025_Raimondi_Gastric-FLOT-nodal_J-Clin-Oncol.md) — *Raimondi A* · PMID 41021880 · [DOI](https://doi.org/10.1200/JCO-25-00447)
- **2025** · [Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.](04_otros_tumores/2025_vanLaarhoven_Esophageal-CROSS-ypN0_EClinicalMedicine.md) — *van Laarhoven H* · PMID 39911244 · PMC11795631 · [DOI](https://doi.org/10.1016/j.eclinm.2024.103067)
- **2025** · [Nodal Downstaging in Patients With Rectal Cancer: Survival Is Promising if YpN0 Is Achieved.](04_otros_tumores/2025_Wan_Rectal-ypN0-prognosis_Dis-Colon-Rectum.md) — *Wan H* · PMID 40626521 · [DOI](https://doi.org/10.1097/DCR.0000000000003846)
- **2025** · [Safety and efficacy of laparoscopic radical gastrectomy after neoadjuvant chemotherapy plus immunotherapy: a retrospective cohort study.](04_otros_tumores/2025_Xiong_Gastric-perioperative_Front-Immunol.md) — *Xiong J* · PMID 40977738 · PMC12443829 · [DOI](https://doi.org/10.3389/fimmu.2025.1672547)
- **2024** · [Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.](04_otros_tumores/2024_Afferi_Bladder-durvalumab_BJU-Int.md) — *Afferi L* · PMID 38456541 · [DOI](https://doi.org/10.1111/bju.16318)
- **2024** · [Income Disparities in Survival and Receipt of Neoadjuvant Chemotherapy and Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer.](04_otros_tumores/2024_Antar_Bladder-PLND_Curr-Oncol.md) — *Antar RM* · PMID 38785473 · PMC11119047 · [DOI](https://doi.org/10.3390/curroncol31050192)
- **2024** · [Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.](04_otros_tumores/2024_Antar_Bladder-PLND_Transl-Androl-Urol.md) — *Antar RM* · PMID 39280687 · PMC11399033 · [DOI](https://doi.org/10.21037/tau-24-165)
- **2024** · [Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer.](04_otros_tumores/2024_Hansen_NSCLC-chemo-IO-ypN0_Explor-Target-Antitumor-Ther.md) — *Hansen T* · PMID 39465010 · PMC11502072 · [DOI](https://doi.org/10.37349/etat.2024.00273)
- **2024** · [Three years follow-up of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.](04_otros_tumores/2024_Ji_NSCLC-chemo-IO-ypN0_Neoplasma.md) — *Ji W* · PMID 38506033 · [DOI](https://doi.org/10.4149/neo_2024_230517N262)
- **2024** · [Neoadjuvant chemotherapy with bevacizumab for locally advanced vulvar cancer.](04_otros_tumores/2024_Kuhn_Gyn-vulvar-NAC_Int-J-Gynecol-Cancer.md) — *Kuhn TM* · PMID 38830645 · [DOI](https://doi.org/10.1136/ijgc-2024-005402)
- **2024** · [Evaluation of pathologic response and surgical safety of total neoadjuvant therapy for patients with clinical stage III gastric cancer in a real-world setting.](04_otros_tumores/2024_Li_Gastric-perioperative_J-Gastrointest-Surg.md) — *Li Z* · PMID 39019340 · [DOI](https://doi.org/10.1016/j.gassur.2024.07.008)
- **2024** · [The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.](04_otros_tumores/2024_Rencuzogullari_Gastric-FLOT-nodal_J-Surg-Oncol.md) — *Rencuzogullari A* · PMID 39400342 · PMC12044282 · [DOI](https://doi.org/10.1002/jso.27934)
- **2024** · [Pathological responses of primary tumor and lymph nodes in non-small cell lung cancer after neoadjuvant chemoimmunotherapy: a retrospective real-world study.](04_otros_tumores/2024_Shao_NSCLC-chemo-IO-ypN0_J-Thorac-Dis.md) — *Shao W* · PMID 39552859 · PMC11565332 · [DOI](https://doi.org/10.21037/jtd-24-1011)
- **2024** · [Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.](04_otros_tumores/2024_Thompson_Rectal-watch-wait_JAMA-Netw-Open.md) — *Thompson HM* · PMID 38194231 · PMC10777257 · [DOI](https://doi.org/10.1001/jamanetworkopen.2023.50903)
- **2023** · [Tri-modality therapy in advanced esophageal carcinoma: long-term results and insights from a developing world, institutional cohort.](04_otros_tumores/2023_Chufal_Esophageal-ypN0_Br-J-Radiol.md) — *Chufal KS* · PMID 36541255 · PMC9975378 · [DOI](https://doi.org/10.1259/bjr.20220413)
- **2023** · [[Pathological pelvic lymph node involvement in muscle-invasive bladder cancer patients treated with radical cystectomy: A narrative review].](04_otros_tumores/2023_Gabriel_Bladder-PLND_Prog-Urol.md) — *Gabriel PE* · PMID 36604248 · [DOI](https://doi.org/10.1016/j.purol.2022.12.013)
- **2023** · [Neoadjuvant therapy in non-small cell lung cancer.](04_otros_tumores/2023_Grant_NSCLC-CheckMate-816_Crit-Rev-Oncol-Hematol.md) — *Grant C* · PMID 37532102 · [DOI](https://doi.org/10.1016/j.critrevonc.2023.104080)
- **2023** · [Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.](04_otros_tumores/2023_Huang_NSCLC-chemo-IO-ypN0_Lung-Cancer.md) — *Huang S* · PMID 37844351 · [DOI](https://doi.org/10.1016/j.lungcan.2023.107401)
- **2023** · [Comparison of perioperative and histopathologic outcomes among neoadjuvant treatment strategies for locoregional gastric cancer.](04_otros_tumores/2023_Janczewski_Gastric-perioperative_J-Surg-Oncol.md) — *Janczewski LM* · PMID 37986548 · PMC10872619 · [DOI](https://doi.org/10.1002/jso.27521)
- **2023** · [Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s63](04_otros_tumores/2023_Lorenzen_Gastric-FLOT-nodal_J-Clin-Oncol.md) — *Lorenzen S* · PMID 37963317 · [DOI](https://doi.org/10.1200/JCO.23.00975)
- **2023** · [Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.](04_otros_tumores/2023_Mitsudomi_NSCLC-CheckMate-816_Cancer-Sci.md) — *Mitsudomi T* · PMID 38098261 · PMC10859619 · [DOI](https://doi.org/10.1111/cas.16030)
- **2023** · [The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced res](04_otros_tumores/2023_Resteghini_HeadNeck-sinonasal-ICT_Eur-J-Cancer.md) — *Resteghini C* · PMID 37164774 · [DOI](https://doi.org/10.1016/j.ejca.2023.03.033)
- **2023** · [Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network.](04_otros_tumores/2023_Tankel_Gastric-FLOT-nodal_Ann-Surg-Oncol.md) — *Tankel J* · PMID 38142255 · [DOI](https://doi.org/10.1245/s10434-023-14779-4)
- **2023** · [Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer.](04_otros_tumores/2023_Zeng_NSCLC-chemo-IO-ypN0_Front-Oncol.md) — *Zeng J* · PMID 36910671 · PMC9996108 · [DOI](https://doi.org/10.3389/fonc.2023.1134713)
- **2023** · [Clinical utility of [F]FDG PET/CT in the assessment of mediastinal lymph node disease after neoadjuvant chemoimmunotherapy for non-small cell lung cancer.](04_otros_tumores/2023_Zhang_NSCLC-mediastinal-downstaging_Eur-Radiol.md) — *Zhang L* · PMID 37464112 · [DOI](https://doi.org/10.1007/s00330-023-09910-8)
- **2022** · [Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.](04_otros_tumores/2022_Forde_NSCLC-CheckMate-816_N-Engl-J-Med.md) — *Forde PM* · PMID 35403841 · PMC9844511 · [DOI](https://doi.org/10.1056/NEJMoa2202170)
- **2022** · [Prognostic Value of Mesorectal Lymph Node Micrometastases in ypN0 Rectal Cancer After Chemoradiation.](04_otros_tumores/2022_Kang_Rectal-ypN0-prognosis_J-Surg-Res.md) — *Kang BM* · PMID 35427909 · [DOI](https://doi.org/10.1016/j.jss.2022.02.040)
- **2022** · [A Nomogram to Predict Nodal Response after Induction Chemotherapy for Hypopharyngeal Carcinoma.](04_otros_tumores/2022_Li_HeadNeck-induction-nodal_Laryngoscope.md) — *Li F* · PMID 35699589 · [DOI](https://doi.org/10.1002/lary.30241)
- **2021** · [Neoadjuvant PD-1 Inhibitors and Chemotherapy for Locally Advanced NSCLC: A Retrospective Study.](04_otros_tumores/2021_Chen_NSCLC-chemo-IO-ypN0_Ann-Thorac-Surg.md) — *Chen T* · PMID 33781737 · [DOI](https://doi.org/10.1016/j.athoracsur.2021.03.041)
- **2021** · [Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma.](04_otros_tumores/2021_Chotard_Rectal-ypN0-prognosis_Virchows-Arch.md) — *Chotard G* · PMID 33983519 · [DOI](https://doi.org/10.1007/s00428-021-03108-3)
- **2021** · [Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.](04_otros_tumores/2021_Galsky_Bladder-perio-pembro_Future-Oncol.md) — *Galsky MD* · PMID 34008425 · [DOI](https://doi.org/10.2217/fon-2021-0273)
- **2021** · [Neo-adjuvant chemotherapy in fertility-sparing cervical cancer treatment.](04_otros_tumores/2021_Kasius_Gyn-cervical-NAC_Best-Pract-Res-Clin-Obstet-Gyna.md) — *Kasius JC* · PMID 33752979 · [DOI](https://doi.org/10.1016/j.bpobgyn.2021.01.010)
- **2021** · [Duration of Perioperative Chemotherapy in Locally Advanced Gastric Cancer: A "Less Is More" Question When ypN0 Is Achieved.](04_otros_tumores/2021_Liu_Gastric-perioperative_Front-Oncol.md) — *Liu Z* · PMID 34926284 · PMC8671134 · [DOI](https://doi.org/10.3389/fonc.2021.775166)
- **2021** · [Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.](04_otros_tumores/2021_Liu_NSCLC-chemo-IO-ypN0_Ann-Thorac-Cardiovasc-Surg.md) — *Liu Z* · PMID 34776459 · PMC9081467 · [DOI](https://doi.org/10.5761/atcs.oa.21-00143)
- **2021** · [Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.](04_otros_tumores/2021_Rahma_Rectal-TNT-ypN0_JAMA-Oncol.md) — *Rahma OE* · PMID 34196693 · PMC8251652 · [DOI](https://doi.org/10.1001/jamaoncol.2021.1683)
- **2021** · [Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.](04_otros_tumores/2021_vanHoogstraten_Bladder-occult-LN_World-J-Urol.md) — *van Hoogstraten LMC* · PMID 34585294 · PMC8813846 · [DOI](https://doi.org/10.1007/s00345-021-03839-7)
- **2021** · [The assessment of risk factors for long-term survival outcome in ypN0 patients with rectal cancer after neoadjuvant therapy and radical anterior resection.](04_otros_tumores/2021_Zeman_Rectal-ypN0-prognosis_World-J-Surg-Oncol.md) — *Zeman M* · PMID 34020673 · PMC8140444 · [DOI](https://doi.org/10.1186/s12957-021-02262-x)
- **2020** · [Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal canc](04_otros_tumores/2020_Bahadoer_Rectal-MRI-nodal_Lancet-Oncol.md) — *Bahadoer RR* · PMID 33301740 · [DOI](https://doi.org/10.1016/S1470-2045(20)30555-6)
- **2020** · [Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.](04_otros_tumores/2020_Iyer_Bladder-PLND_Clin-Genitourin-Cancer.md) — *Iyer G* · PMID 32273235 · PMC8375301 · [DOI](https://doi.org/10.1016/j.clgc.2020.02.014)
- **2020** · [Low rectal cancer treatment strategies: a cohort study assessing watch and wait.](04_otros_tumores/2020_Pinto_Rectal-watch-wait_J-Cancer-Res-Clin-Oncol.md) — *Pinto JC* · PMID 32435893 · PMC11804403 · [DOI](https://doi.org/10.1007/s00432-020-03248-0)
- **2020** · [Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.](04_otros_tumores/2020_Zhang_Esophageal-active-surveillance_BMC-Cancer.md) — *Zhang X* · PMID 32143580 · PMC7060643 · [DOI](https://doi.org/10.1186/s12885-020-6669-y)
- **2020** · [[Key points of perioperative whole-process management for patients with advanced gastric cancer].](04_otros_tumores/2020_Zhu_Gastric-perioperative_Zhonghua-Wei-Chang-Wai-Ke-Za-.md) — *Zhu ZG* · PMID 32074789 · [DOI](https://doi.org/10.3760/cma.j.issn.1671-0274.2020.02.004)
- **2019** · [Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer.](04_otros_tumores/2019_Allen_Gastric-perioperative_Ann-Surg-Oncol.md) — *Allen CJ* · PMID 31552618 · [DOI](https://doi.org/10.1245/s10434-019-07840-8)
- **2019** · [YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence.](04_otros_tumores/2019_Manceau_Rectal-ypN0-prognosis_Dig-Liver-Dis.md) — *Manceau G* · PMID 31427089 · [DOI](https://doi.org/10.1016/j.dld.2019.07.013)
- **2019** · [[The significance of lymph node yield in rectal cancer after neoadjuvant chemotherapy].](04_otros_tumores/2019_Zhu_Rectal-ypN0-prognosis_Zhonghua-Wei-Chang-Wai-Ke-Za-.md) — *Zhu LY* · PMID 31550831 · [DOI](https://doi.org/10.3760/cma.j.issn.1671-0274.2019.09.016)
- **2017** · [Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study.](04_otros_tumores/2017_Favi_Gastric-FLOT-nodal_Eur-J-Surg-Oncol.md) — *Favi F* · PMID 28666624 · [DOI](https://doi.org/10.1016/j.ejso.2017.06.003)
- **2017** · [Clinical outcomes and benefits for staging of surgical lymph node mapping after esophagectomy.](04_otros_tumores/2017_Lagarde_Esophageal-LN-prognosis_Dis-Esophagus.md) — *Lagarde SM* · PMID 28881884 · [DOI](https://doi.org/10.1093/dote/dox086)
- **----** · [Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis.](04_otros_tumores/2019_Zhu_Rectal-neoadj-nodal_Medicine-(Baltimore).md) — *Zhu J* · PMID 31027072 · PMC6831214 · [DOI](https://doi.org/10.1097/MD.0000000000015241)
- **----** · [Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis.](04_otros_tumores/2021_dePascale_Esophageal-CROSS-ypN0_Cancers-(Basel).md) — *de Pascale S* · PMID 33562316 · PMC7915215 · [DOI](https://doi.org/10.3390/cancers13040666)
- **----** · [Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective.](04_otros_tumores/2021_Pelc_Gastric-perioperative_Cancers-(Basel).md) — *Pelc Z* · PMID 34065596 · PMC8160868 · [DOI](https://doi.org/10.3390/cancers13102509)
- **----** · [Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+).](04_otros_tumores/2022_Max142kiewicz_Bladder-PLND_Cancers-(Basel).md) — *Ma&#x142;kiewicz B* · PMID 36358705 · PMC9656528 · [DOI](https://doi.org/10.3390/cancers14215286)
- **----** · [Adequate Pelvic Lymph Node Dissection in Radical Cystectomy in the Era of Neoadjuvant Chemotherapy: A Meta-Analysis and Systematic Review.](04_otros_tumores/2023_Kaczmarek_Bladder-PLND_Cancers-(Basel).md) — *Kaczmarek K* · PMID 37627068 · PMC10452598 · [DOI](https://doi.org/10.3390/cancers15164040)
- **----** · [Interleukin-6 as a Predictive Factor of Pathological Response to FLOT Regimen Systemic Treatment in Locally Advanced Gastroesophageal Junction or Gastric Cancer Patients.](04_otros_tumores/2024_MarciszGrzanka_Gastric-FLOT-nodal_Cancers-(Basel).md) — *Marcisz-Grzanka K* · PMID 38398148 · PMC10887209 · [DOI](https://doi.org/10.3390/cancers16040757)
- **----** · [The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.](04_otros_tumores/2024_Mayenga_NSCLC-CheckMate-816_Breathe-(Sheff).md) — *Mayenga M* · PMID 39534491 · PMC11555582 · [DOI](https://doi.org/10.1183/20734735.0044-2024)
- **----** · [Oncological outcomes of patients with node positive disease following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: A multicenter observational study of the EAU Y](04_otros_tumores/2025_Marcq_Bladder-PLND_Actas-Urol-Esp-(Engl-Ed).md) — *Marcq G* · PMID 39938643 · [DOI](https://doi.org/10.1016/j.acuroe.2025.501701)

## 05 — Técnicas quirúrgicas (TAD, SLNB)

- **2025** · [Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study.](05_tecnicas_quirurgicas_TAD_SLNB/2025_Kxfchn_TAD_Br-J-Surg.md) — *K&#xfc;hn Thorsten* · PMID 40966675 · [DOI](https://doi.org/10.1093/bjs/znaf180)
- **2024** · [Omisión de Linfadenectomía Axilar tras Negativización Nodal con Neoadyuvancia (Multicéntrico Internacional)](05_tecnicas_quirurgicas_TAD_SLNB/2024_Montagna_OmisionALND-ypN0_JAMA-Oncol.md) — *Montagna G* · PMID 38662396 · PMC11046400 · [DOI](https://doi.org/10.1001/jamaoncol.2024.0578)
- **2023** · [Technetium-99-Guided Axillary Lymph Node Identification: A Case Report of a Novel Technique for Targeted Lymph Node Excision Biopsy for Node Positive Breast Cancer After Neoadjuvant Chemotherapy.](05_tecnicas_quirurgicas_TAD_SLNB/2023_Copeland_TAD-NAC-institutional_JMedCase.md) — *Copeland JE* · PMID 38186556 · PMC10769653 · [DOI](https://doi.org/10.14740/jmc4172)
- **2023** · [Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients.](05_tecnicas_quirurgicas_TAD_SLNB/2023_Del_TAD-NAC-institutional_EurJSurg.md) — *Del Castillo A* · PMID 36958951 · [DOI](https://doi.org/10.1016/j.ejso.2023.03.208)
- **2023** · [SenTa Registry — Safety of TAD After Neoadjuvant Therapy (German Multicenter Prospective)](05_tecnicas_quirurgicas_TAD_SLNB/2023_Kuemmel_SenTa_TAD-safety_JAMA-Surg.md) — *Kuemmel S* · PMID 37285140 · PMC10248815 · [DOI](https://doi.org/10.1001/jamasurg.2023.1772)
- **2023** · [Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy.](05_tecnicas_quirurgicas_TAD_SLNB/2023_Lim_cN+-a-ypN0_Breast-Cancer-Res-Treat.md) — *Lim Sue Zann* · PMID 37796365 · [DOI](https://doi.org/10.1007/s10549-023-07104-w)
- **2022** · [Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.](05_tecnicas_quirurgicas_TAD_SLNB/2022_Aragon-Sanchez_cN+-a-ypN0_Breast-J.md) — *Aragon-Sanchez Sofia* · PMID 36051467 · PMC9411000 · [DOI](https://doi.org/10.1155/2022/1507881)
- **2022** · [Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes.](05_tecnicas_quirurgicas_TAD_SLNB/2022_Haque_SLNB-post-NAC_Clin-Breast-Cancer.md) — *Haque Waqar* · PMID 35193807 · [DOI](https://doi.org/10.1016/j.clbc.2022.01.006)
- **2022** · [Update on sentinel node pathology in breast cancer.](05_tecnicas_quirurgicas_TAD_SLNB/2022_Harrison_SLNB-post-NAC_Semin-Diagn-Pathol.md) — *Harrison Beth* · PMID 35803776 · [DOI](https://doi.org/10.1053/j.semdp.2022.06.016)
- **2021** · [Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?](05_tecnicas_quirurgicas_TAD_SLNB/2021_Alarcxfn_TAD-NAC-institutional_Surgeon.md) — *Alarc&#xf3;n M* · PMID 33663946 · [DOI](https://doi.org/10.1016/j.surge.2021.01.013)
- **2021** · [Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease.](05_tecnicas_quirurgicas_TAD_SLNB/2021_Goel_SLNB-post-NAC_J-Surg-Oncol.md) — *Goel Neha* · PMID 33852160 · [DOI](https://doi.org/10.1002/jso.26480)
- **2020** · [Sentinel Lymph Node Biopsy in Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy-an Indian Perspective.](05_tecnicas_quirurgicas_TAD_SLNB/2020_Arjunan_SLNB-post-NAC_Indian-J-Surg-Oncol.md) — *Arjunan Ravi* · PMID 32523270 · PMC7260325 · [DOI](https://doi.org/10.1007/s13193-020-01035-4)
- **2020** · [Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy](05_tecnicas_quirurgicas_TAD_SLNB/2020_BottyVanDenBruele_Occult-primary_Ann-Surg-Oncol.md) — *Astrid Botty Van den Bruele* · PMID 32813202 · PMC7855271 · [DOI](https://doi.org/10.1245/s10434-020-08863-2)
- **2020** · [Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.](05_tecnicas_quirurgicas_TAD_SLNB/2020_Damin_cN+-a-ypN0_Breast-Cancer-Res-Treat.md) — *Damin Andrea P* · PMID 33165710 · [DOI](https://doi.org/10.1007/s10549-020-06011-8)
- **2020** · [Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study.](05_tecnicas_quirurgicas_TAD_SLNB/2020_Garcxeda-Novoa_TAD-NAC-institutional_AnnSurgOnco.md) — *Garc&#xed;a-Novoa A* · PMID 32725521 · [DOI](https://doi.org/10.1245/s10434-020-08925-5)
- **2020** · [Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis.](05_tecnicas_quirurgicas_TAD_SLNB/2020_Kolberg_SLNB-post-NAC_Geburtshilfe-Frauenheilkd.md) — *Kolberg Hans-Christian* · PMID 33293731 · PMC7714621 · [DOI](https://doi.org/10.1055/a-1298-3453)
- **2020** · [Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers.](05_tecnicas_quirurgicas_TAD_SLNB/2020_Laws_TAD-NAC-institutional_AnnSurgOnco.md) — *Laws A* · PMID 32740737 · [DOI](https://doi.org/10.1245/s10434-020-08902-y)
- **2020** · [Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization.](05_tecnicas_quirurgicas_TAD_SLNB/2020_Sun_TAD-NAC-institutional_ClinBreaCanc.md) — *Sun J* · PMID 32893094 · [DOI](https://doi.org/10.1016/j.clbc.2020.08.001)
- **2019** · [Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy.](05_tecnicas_quirurgicas_TAD_SLNB/2019_Hellingman_TAD-NAC-institutional_EJNMMIRes.md) — *Hellingman D* · PMID 31650284 · PMC6811805 · [DOI](https://doi.org/10.1186/s13550-019-0560-3)
- **2019** · [Targeted axillary dissection after neoadjuvant systemic therapy in patients with node-positive breast cancer.](05_tecnicas_quirurgicas_TAD_SLNB/2019_Kanesalingam_TAD-NAC-institutional_AnzJSurg.md) — *Kanesalingam K* · PMID 31845501 · [DOI](https://doi.org/10.1111/ans.15604)
- **2019** · [Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.](05_tecnicas_quirurgicas_TAD_SLNB/2019_Srour_cN+-a-ypN0_Ann-Surg-Oncol.md) — *Srour Marissa K* · PMID 31342364 · [DOI](https://doi.org/10.1245/s10434-019-07540-3)
- **2017** · [Evolution in sentinel lymph node biopsy in breast cancer.](05_tecnicas_quirurgicas_TAD_SLNB/2017_Qiu_cN+-a-ypN0_Crit-Rev-Oncol-Hematol.md) — *Qiu Si-Qi* · PMID 29482783 · [DOI](https://doi.org/10.1016/j.critrevonc.2017.09.010)
- **2016** · [Targeted Axillary Dissection (TAD) — Caudle et al. (Implementation of TAD)](05_tecnicas_quirurgicas_TAD_SLNB/2016_Caudle_TAD_Original_JCO.md) — *Caudle AS* · PMID 26811528 · PMC4933133 · [DOI](https://doi.org/10.1200/JCO.2015.64.0094)
- **2016** · [CT-Guided Wire Localization for Involved Axillary Lymph Nodes After Neo-adjuvant Chemotherapy in Patients With Initially Node-Positive Breast Cancer.](05_tecnicas_quirurgicas_TAD_SLNB/2016_Trinh_TAD-NAC-institutional_BreastJ.md) — *Trinh L* · PMID 27061012 · [DOI](https://doi.org/10.1111/tbj.12597)
- **2015** · [Management of axilla in breast cancer - The saga continues.](05_tecnicas_quirurgicas_TAD_SLNB/2015_Layeequr-Rahman_NAC-axila_Breast.md) — *Layeequr Rahman Rakhshanda* · PMID 25937264 · [DOI](https://doi.org/10.1016/j.breast.2015.03.010)
- **----** · [Review of the role of the sentinel node biopsy in neoadjuvant chemotherapy in women with breast cancer and negative or positive axillary node at diagnosis.](05_tecnicas_quirurgicas_TAD_SLNB/2017_Ruano-Pxe9rez_cN+-a-ypN0_Rev-Esp-Med-Nucl-Imagen-Mol-Engl-Ed.md) — *Ruano P&#xe9;rez R* · PMID 28869178 · [DOI](https://doi.org/10.1016/j.remn.2017.06.007)
- **----** · [The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers](05_tecnicas_quirurgicas_TAD_SLNB/2020_Flores-Funes_TAD-review_Cir-Esp.md) — *Diego Flores-Funes* · PMID 32386728 · [DOI](https://doi.org/10.1016/j.ciresp.2020.03.012)
- **----** · [False Negativity of Targeted Axillary Dissection in Breast Cancer](05_tecnicas_quirurgicas_TAD_SLNB/2021_Kirkilesis_TAD-FNR_Breast-Care.md) — *George Kirkilesis* · PMID 34720813 · PMC8543285 · [DOI](https://doi.org/10.1159/000513037)
- **----** · [Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer.](05_tecnicas_quirurgicas_TAD_SLNB/2021_Murthy_TAD-NAC-institutional_CancersBasel.md) — *Murthy V* · PMID 34439321 · PMC8394061 · [DOI](https://doi.org/10.3390/cancers13164167)
- **----** · [Patients with initial nodal involvement due to breast cancer who have received neoadjuvant chemotherapy: Combined sentinel node-radioguided surgery of the pathological node.](05_tecnicas_quirurgicas_TAD_SLNB/2022_Fuertes_TAD-NAC-institutional_RevEspMed.md) — *Fuertes Manuel J* · PMID 35597764 · [DOI](https://doi.org/10.1016/j.remnie.2022.05.002)
- **----** · [Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Neo-Adjuvant Chemotherapy: Clinical Experience with Node-Negative and Node-Positive Disease Prior to Systemic Therapy.](05_tecnicas_quirurgicas_TAD_SLNB/2023_Tinterri_cN+-a-ypN0_Cancers-Basel.md) — *Tinterri Corrado* · PMID 36980605 · PMC10046076 · [DOI](https://doi.org/10.3390/cancers15061719)
- **----** · [Resumen ejecutivo — Targeted Axillary Dissection (TAD): técnica, evidencia y pitfalls](05_tecnicas_quirurgicas_TAD_SLNB/RESUMEN_01_TAD_tecnica.md) — *?* · 

## 06 — Imagen, marcaje y predicción

- **2024** · [Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.](06_imagen_y_marcaje/2024_Akdag_NAC-axila_Chemotherapy.md) — *Akdag Goncagul* · PMID 38368871 · [DOI](https://doi.org/10.1159/000537874)
- **2024** · [Evaluating Magnetic Seed Localization in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Receiving Neoadjuvant Systemic Therapy: A Comprehensive Review and Pooled Analysis](06_imagen_y_marcaje/2024_Alamoodi_Magseed-TAD_J-Clin-Med.md) — *Munaser Alamoodi* · PMID 38792449 · PMC11122577 · [DOI](https://doi.org/10.3390/jcm13102908)
- **2024** · [The use of blue dye alone for sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer.](06_imagen_y_marcaje/2024_Cavalcante_Clip-marker_Eur-J-Surg-Oncol.md) — *Cavalcante Francisco Pimentel* · PMID 38262300 · [DOI](https://doi.org/10.1016/j.ejso.2024.107967)
- **2024** · [Delta Radiomics Based on MRI for Predicting Axillary Lymph Node Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients.](06_imagen_y_marcaje/2024_Mao_NAC-axila_Acad-Radiol.md) — *Mao Ning* · PMID 39271381 · [DOI](https://doi.org/10.1016/j.acra.2024.07.052)
- **2024** · [An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.](06_imagen_y_marcaje/2024_Zheng_cN+-a-ypN0_Cancer.md) — *Zheng Qijun* · PMID 38427584 · [DOI](https://doi.org/10.1002/cncr.35248)
- **2023** · [Outcomes of Sentinel Lymph Node Biopsy for Patients With Node-positive Breast Cancer Treated With Neoadjuvant Chemotherapy.](06_imagen_y_marcaje/2023_Cipolla_cN+-a-ypN0_Anticancer-Res.md) — *Cipolla Calogero* · PMID 37772556 · [DOI](https://doi.org/10.21873/anticanres.16659)
- **2023** · [Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact.](06_imagen_y_marcaje/2023_Jankowski_cN+-a-ypN0_Bull-Cancer.md) — *Jankowski Cl&#xe9;mentine* · PMID 37080848 · [DOI](https://doi.org/10.1016/j.bulcan.2023.03.009)
- **2023** · [The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience.](06_imagen_y_marcaje/2023_Tercan_cN+-a-ypN0_Breast-J.md) — *Tercan Ismail Can* · PMID 36694670 · PMC9833895 · [DOI](https://doi.org/10.1155/2023/4549033)
- **2023** · [This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients.](06_imagen_y_marcaje/2023_van-Hemert_TAD_Breast.md) — *van Hemert Annemiek K E* · PMID 37562108 · PMC10432821 · [DOI](https://doi.org/10.1016/j.breast.2023.06.011)
- **2022** · [Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study.](06_imagen_y_marcaje/2022_Hartmann_TAD_Geburtshilfe-Frauenheilkd.md) — *Hartmann Steffi* · PMID 36110892 · PMC9470287 · [DOI](https://doi.org/10.1055/a-1889-7883)
- **2021** · [Role of the radiologist during neoadjuvant systemic therapy for breast cancer.](06_imagen_y_marcaje/2021_Houserkovxe1_NAC-axila_Rozhl-Chir.md) — *Houserkov&#xe1; D* · PMID 34465118 · [DOI](https://doi.org/10.33699/PIS.2021.100.6.285-294)
- **2020** · [Axillary Nodal Evaluation in Breast Cancer: State of the Art](06_imagen_y_marcaje/2020_Chang_Axillary-nodal-evaluation_Radiology.md) — *Jung Min Chang* · PMID 32315268 · [DOI](https://doi.org/10.1148/radiol.2020192534)
- **2019** · [Imaging-Based Approach to Axillary Lymph Node Staging and Sentinel Lymph Node Biopsy in Patients With Breast Cancer.](06_imagen_y_marcaje/2019_Sun_SLNB-post-NAC_AJR-Am-J-Roentgenol.md) — *Sun Susie X* · PMID 31714846 · [DOI](https://doi.org/10.2214/AJR.19.22022)
- **2017** · [Role of DWI assessing nodal involvement and response to neoadjuvant chemotherapy in advanced breast cancer.](06_imagen_y_marcaje/2017_Belli_NAC-axila_Eur-Rev-Med-Pharmacol-Sci.md) — *Belli P* · PMID 28272714
- **2017** · [Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.](06_imagen_y_marcaje/2017_Caudle_Radioterapia-NAC_Ann-Surg-Oncol.md) — *Caudle Abigail S* · PMID 28766207 · PMC5759951 · [DOI](https://doi.org/10.1245/s10434-017-5958-4)
- **2017** · [Application of ACOSOG Z1071: Effect of Results on Patient Care and Surgical Decision-Making.](06_imagen_y_marcaje/2017_Palmer_cN+-a-ypN0_Clin-Breast-Cancer.md) — *Palmer Jacquelyn A V* · PMID 29129549 · [DOI](https://doi.org/10.1016/j.clbc.2017.10.006)
- **2017** · [Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.](06_imagen_y_marcaje/2017_Spring_cN+-a-ypN0_J-Natl-Compr-Canc-Netw.md) — *Spring Laura* · PMID 28982747 · [DOI](https://doi.org/10.6004/jnccn.2017.0158)
- **2016** · [Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.](06_imagen_y_marcaje/2016_Diego_Clip-marker_Ann-Surg-Oncol.md) — *Diego Emilia J* · PMID 26727919 · [DOI](https://doi.org/10.1245/s10434-015-5052-8)
- **2016** · [Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.](06_imagen_y_marcaje/2016_El-Hage-Chehade_cN+-a-ypN0_Anticancer-Res.md) — *El Hage Chehade Hiba* · PMID 27069121
- **2001** · [Application of the Z1071 criteria: classification of axillary lymph nodes on ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer.](06_imagen_y_marcaje/2020_Iwamoto_cN+-a-ypN0_J-Med-Ultrason-2001.md) — *Iwamoto Naoko* · PMID 32112307 · [DOI](https://doi.org/10.1007/s10396-020-01010-0)
- **----** · [Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Ration](06_imagen_y_marcaje/2021_Banys-Paluchowski_TAD_Cancers-Basel.md) — *Banys-Paluchowski Maggie* · PMID 33805367 · PMC8037995 · [DOI](https://doi.org/10.3390/cancers13071565)
- **----** · [Marking Techniques for Targeted Axillary Dissection Among Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy](06_imagen_y_marcaje/2023_Gante_Marking-techniques-TAD_Breast-Cancer.md) — *Inês Gante* · PMID 37255883 · PMC10226338 · [DOI](https://doi.org/10.1177/11782234231176159)
- **----** · [Assessing the Efficacy of Radioactive Iodine Seed Localisation in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy: A Systematic Revi](06_imagen_y_marcaje/2024_Alamoodi_Radioactive-seed-TAD_Diagnostics.md) — *Munaser Alamoodi* · PMID 38893701 · PMC11172271 · [DOI](https://doi.org/10.3390/diagnostics14111175)
- **----** · [Abemaciclib for the Treatment of HR+HER2- Metastatic Breast Cancer: An Institutional Experience.](06_imagen_y_marcaje/2024_Matos_Axila-NAC_Cancers-Basel.md) — *Matos Erika* · PMID 38791907 · PMC11119494 · [DOI](https://doi.org/10.3390/cancers16101828)
- **----** · [Evaluating Radar Reflector Localisation in Targeted Axillary Dissection in Patients Undergoing Neoadjuvant Systemic Therapy for Node-Positive Early Breast Cancer: A Systematic Review and Pooled Analys](06_imagen_y_marcaje/2024_Wazir_Radar-reflector-TAD_Cancers.md) — *Umar Wazir* · PMID 38611023 · PMC11011109 · [DOI](https://doi.org/10.3390/cancers16071345)
- **----** · [Resumen ejecutivo — Marcaje del ganglio biopsiado pre-NAC: comparativa pragmática](06_imagen_y_marcaje/RESUMEN_02_marcaje_comparativo.md) — *?* · 

## 07 — Anatomía patológica

- **2025** · [Predictors of Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer.](07_anatomia_patologica/2025_An_cN+-a-ypN0_Ann-Surg-Oncol.md) — *An Selena J* · PMID 40684017 · PMC12371429 · [DOI](https://doi.org/10.1245/s10434-025-17906-5)
- **2025** · [Comparison of 10-Year Survival Between Patients With Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy and Patients With Initially Negative Nodes in Breast Cancer.](07_anatomia_patologica/2025_Wang_cN+-a-ypN0_Clin-Breast-Cancer.md) — *Wang Jiwei* · PMID 40038007 · [DOI](https://doi.org/10.1016/j.clbc.2025.02.006)
- **2023** · [Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy.](07_anatomia_patologica/2023_Flores_NAC-axila_Ann-Surg-Oncol.md) — *Flores Rene* · PMID 37606840 · [DOI](https://doi.org/10.1245/s10434-023-14082-2)
- **2023** · [Correlation between breast and axillary pathologic complete response after neoadjuvant chemotherapy in breast cancer.](07_anatomia_patologica/2023_Yx131ldx131rx131m_NAC-axila_Ann-Ital-Chir.md) — *Y&#x131;ld&#x131;r&#x131;m Emine* · PMID 37794792
- **2022** · [Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk.](07_anatomia_patologica/2022_Boughey_cN+-a-ypN0_Ann-Surg-Oncol.md) — *Boughey Judy C* · PMID 35876925 · [DOI](https://doi.org/10.1245/s10434-022-12191-y)
- **2022** · [Deep learning radiomics of ultrasonography for comprehensively predicting tumor and axillary lymph node status after neoadjuvant chemotherapy in breast cancer patients: A multicenter study.](07_anatomia_patologica/2022_Gu_NAC-axila_Cancer.md) — *Gu Jionghui* · PMID 36401611 · [DOI](https://doi.org/10.1002/cncr.34540)
- **2021** · [Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer.](07_anatomia_patologica/2021_Lim_cN+-a-ypN0_Ann-Surg-Oncol.md) — *Lim David W* · PMID 34374914 · [DOI](https://doi.org/10.1245/s10434-021-10519-8)
- **2021** · [Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.](07_anatomia_patologica/2021_Myers_cN+-a-ypN0_Ann-Surg-Oncol.md) — *Myers Sara P* · PMID 34142288 · [DOI](https://doi.org/10.1245/s10434-021-10195-8)
- **2020** · [Neoadjuvant chemotherapy for luminal a breast cancer: Factors predictive of histopathologic response and oncologic outcome.](07_anatomia_patologica/2020_Collins_cN+-a-ypN0_Am-J-Surg.md) — *Collins Patrick M* · PMID 33334569 · [DOI](https://doi.org/10.1016/j.amjsurg.2020.11.053)
- **2007** · [Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.](07_anatomia_patologica/2007_Symmans_NAC-axila_J-Clin-Oncol.md) — *Symmans W Fraser* · PMID 17785706 · [DOI](https://doi.org/10.1200/JCO.2007.10.6823)
- **----** · [Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy.](07_anatomia_patologica/2018_Liedtke_SLNB-post-NAC_Breast-Care-Basel.md) — *Liedtke Cornelia* · PMID 30800039 · PMC6381911 · [DOI](https://doi.org/10.1159/000489565)
- **----** · [Resumen ejecutivo — Patología axilar post-NAC: cómo procesar y reportar](07_anatomia_patologica/RESUMEN_04_patologia_postNAC.md) — *?* · 

## 08 — Guías clínicas

- **2025** · [Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.](08_guias_clinicas/2025_Park_ASCO-SLN-update_J-Clin-Oncol.md) — *Park KU* · PMID 40209128 · [DOI](https://doi.org/10.1200/JCO-25-00099)
- **2025** · [AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025.](08_guias_clinicas/2025_Reimer_AGO-surgical-therapy-2025_Eur-J-Surg-Oncol.md) — *Reimer T* · PMID 40983010 · [DOI](https://doi.org/10.1016/j.ejso.2025.110445)
- **2025** · [Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations.](08_guias_clinicas/2025_Untch_St-Gallen-2025-treatment_Geburtshilfe-Frauenheilkd.md) — *Untch M* · PMID 40599897 · PMC12208719 · [DOI](https://doi.org/10.1055/a-2612-3790)
- **2024** · [Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.](08_guias_clinicas/2024_Park_ESMO-Pan-Asian-early-breast-cancer_ESMO-Open.md) — *Park KH* · PMID 38796284 · PMC11145753 · [DOI](https://doi.org/10.1016/j.esmoop.2024.102974)
- **2023** · [Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.](08_guias_clinicas/2023_Curigliano_St-Gallen-consensus-2023_Ann-Oncol.md) — *Curigliano G* · PMID 37683978 · [DOI](https://doi.org/10.1016/j.annonc.2023.08.017)
- **2023** · [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.](08_guias_clinicas/2023_Loibl_ESMO-early-breast-cancer-guideline_Ann-Oncol.md) — *Loibl S* · PMID 38101773 · [DOI](https://doi.org/10.1016/j.annonc.2023.11.016)
- **2023** · [EUSOMA quality indicators for non-metastatic breast cancer: An update.](08_guias_clinicas/2023_Rubio_EUSOMA-quality-indicators-update_Eur-J-Cancer.md) — *Rubio IT* · PMID 38199146 · [DOI](https://doi.org/10.1016/j.ejca.2023.113500)
- **2023** · [Uncertainties and controversies in axillary management of patients with breast cancer.](08_guias_clinicas/2023_Weber_EUBREAST-axillary-uncertainties_Cancer-Treat-Rev.md) — *Weber WP* · PMID 37126938 · PMC10752145 · [DOI](https://doi.org/10.1016/j.ctrv.2023.102556)
- **2022** · [AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022.](08_guias_clinicas/2022_Banys-Paluchowski_AGO-surgical-therapy-2022_Geburtshilfe-Frauenheilkd.md) — *Banys-Paluchowski M* · PMID 36186147 · PMC9525149 · [DOI](https://doi.org/10.1055/a-1904-6231)
- **2022** · [Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey.](08_guias_clinicas/2022_Gasparri_EUBREAST-survey-axillary-postNAC_Br-J-Surg.md) — *Gasparri ML* · PMID 35766257 · [DOI](https://doi.org/10.1093/bjs/znac217)
- **2021** · [Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.](08_guias_clinicas/2021_Brackstone_ASCO-Ontario-axilla-management_J-Clin-Oncol.md) — *Brackstone M* · PMID 34279999 · [DOI](https://doi.org/10.1200/JCO.21.00934)
- **2021** · [Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.](08_guias_clinicas/2021_Burstein_St-Gallen-consensus-2021_Ann-Oncol.md) — *Burstein HJ* · PMID 34242744 · PMC9906308 · [DOI](https://doi.org/10.1016/j.annonc.2021.06.023)
- **2020** · [The requirements of a specialist breast centre.](08_guias_clinicas/2020_Biganzoli_EUSOMA-specialist-breast-centre_Breast.md) — *Biganzoli L* · PMID 32217457 · PMC7375681 · [DOI](https://doi.org/10.1016/j.breast.2020.02.003)
- **2019** · [Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.](08_guias_clinicas/2019_Burstein_St-Gallen-consensus-2019_Ann-Oncol.md) — *Burstein HJ* · PMID 31373601 · [DOI](https://doi.org/10.1093/annonc/mdz235)
- **2019** · [Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.](08_guias_clinicas/2019_Cardoso_ESMO-early-breast-cancer-2019_Ann-Oncol.md) — *Cardoso F* · PMID 31161190 · [DOI](https://doi.org/10.1093/annonc/mdz173)
- **2017** · [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.](08_guias_clinicas/2017_Curigliano_St-Gallen-consensus-2017_Ann-Oncol.md) — *Curigliano G* · PMID 28838210 · PMC6246241 · [DOI](https://doi.org/10.1093/annonc/mdx308)
- **2015** · [Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.](08_guias_clinicas/2015_Coates_St-Gallen-consensus-2015_Ann-Oncol.md) — *Coates AS* · PMID 25939896 · PMC4511219 · [DOI](https://doi.org/10.1093/annonc/mdv221)
- **2015** · [Contouring Guidelines for the Axillary Lymph Nodes for the Delivery of Radiation Therapy in Breast Cancer: Evaluation of the RTOG Breast Cancer Atlas.](08_guias_clinicas/2015_Gentile_Radioterapia-NAC_Int-J-Radiat-Oncol-Biol-Phys.md) — *Gentile Michelle S* · PMID 26383674 · PMC12422023 · [DOI](https://doi.org/10.1016/j.ijrobp.2015.07.002)
- **----** · [St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment.](08_guias_clinicas/2019_Balic_St-Gallen-Vienna-2019-brief_Breast-Care-(Basel).md) — *Balic M* · PMID 31798382 · PMC6886108 · [DOI](https://doi.org/10.1159/000499931)
- **----** · [European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes.](08_guias_clinicas/2019_Biganzoli_EUSOMA-organisation-breast-centres_Breast-Care-(Basel).md) — *Biganzoli L* · PMID 31933581 · PMC6940462 · [DOI](https://doi.org/10.1159/000503603)
- **----** · [AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.](08_guias_clinicas/2022_Ditsch_AGO-diagnosis-treatment-2022_Breast-Care-(Basel).md) — *Ditsch N* · PMID 36156915 · PMC9453658 · [DOI](https://doi.org/10.1159/000524879)
- **----** · [St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer - A Brief Summary of the Consensus Discussion.](08_guias_clinicas/2023_Balic_St-Gallen-Vienna-2023-brief_Breast-Care-(Basel).md) — *Balic M* · PMID 37383954 · PMC10294024 · [DOI](https://doi.org/10.1159/000530584)
- **----** · [Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.](08_guias_clinicas/2023_Park-Simon_AGO-diagnosis-treatment-2023_Breast-Care-(Basel).md) — *Park-Simon TW* · PMID 37900552 · PMC10601667 · [DOI](https://doi.org/10.1159/000531578)
- **----** · [Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.](08_guias_clinicas/2024_Park-Simon_AGO-diagnosis-treatment-2024_Breast-Care-(Basel).md) — *Park-Simon TW* · PMID 38894952 · PMC11182637 · [DOI](https://doi.org/10.1159/000538596)
- **----** · [St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference.](08_guias_clinicas/2025_Ditsch_St-Gallen-Vienna-2025-brief_Breast-Care-(Basel).md) — *Ditsch N* · PMID 40546709 · PMC12180904 · [DOI](https://doi.org/10.1159/000546080)
- **----** · [A Decade of AGO QS-Mamma: Adherence to the Recommendations of the AGO Breast Committee for Diagnosis and Treatment in EBC in Routine Therapy in Germany.](08_guias_clinicas/2025_Jackisch_AGO-QS-Mamma-decade_Breast-Care-(Basel).md) — *Jackisch C* · PMID 40256678 · PMC12005700 · [DOI](https://doi.org/10.1159/000543237)
- **----** · [AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.](08_guias_clinicas/2025_Park-Simon_AGO-diagnosis-treatment-2025_Breast-Care-(Basel).md) — *Park-Simon TW* · PMID 40236659 · PMC11996201 · [DOI](https://doi.org/10.1159/000545019)
- **----** · [Resumen comparativo de guias clinicas: manejo axilar en cN+ -> ypN0 tras NAC](08_guias_clinicas/RESUMEN_GUIAS_COMPARATIVO.md) — *?* · 

## 09 — Radioterapia adaptada post-NAC

- **2026** · [Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort](09_radioterapia_post_NAC/2026_Montagna_TAD_Lancet-Oncol.md) — *Montagna Giacomo* · PMID 41449148 · PMC12883204 · [DOI](https://doi.org/10.1016/S1470-2045(25)00598-4)
- **2025** · [Radiotherapy in breast cancer patients achieving nodal pathologic complete response after neoadjuvant therapy: a scoping review.](09_radioterapia_post_NAC/2025_Cavalcante_Radioterapia-NAC_Transl-Breast-Cancer-Res.md) — *Cavalcante Francisco Pimentel* · PMID 40421156 · PMC12104955 · [DOI](https://doi.org/10.21037/tbcr-24-54)
- **2025** · [Rewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision.](09_radioterapia_post_NAC/2025_Habibi_Radioterapia-NAC_NPJ-Breast-Cancer.md) — *Habibi Mehran* · PMID 41193475 · PMC12589602 · [DOI](https://doi.org/10.1038/s41523-025-00819-7)
- **2024** · [Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?](09_radioterapia_post_NAC/2024_Tan_PMRT-ypN0_Breast-Cancer-Res-Treat.md) — *Chen-Feng Tan* · PMID 38616207 · [DOI](https://doi.org/10.1007/s10549-024-07249-2)
- **2023** · [Pathologic Complete Response and Oncologic Outcomes in Locally Advanced Breast Cancers Treated With Neoadjuvant Radiation Therapy: An Australian Perspective.](09_radioterapia_post_NAC/2023_Lin_Radioterapia-NAC_Pract-Radiat-Oncol.md) — *Lin Yuan-Hong* · PMID 36599393 · [DOI](https://doi.org/10.1016/j.prro.2022.12.004)
- **2021** · [Regional Nodal Irradiation for Clinically Node-Positive Breast Cancer Patients With Pathologic Negative Nodes After Neoadjuvant Chemotherapy.](09_radioterapia_post_NAC/2021_Schlafstein_Radioterapia-NAC_Clin-Breast-Cancer.md) — *Schlafstein Ashley* · PMID 34229943 · [DOI](https://doi.org/10.1016/j.clbc.2021.06.003)
- **2021** · [The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis](09_radioterapia_post_NAC/2021_Wang_PMRT-ypN0-metaanalysis_BMC-Cancer.md) — *Ke Wang* · PMID 34172014 · PMC8234630 · [DOI](https://doi.org/10.1186/s12885-021-08423-1)
- **----** · [Resumen ejecutivo — Radioterapia regional post-NAC: estado del arte 2025-2026](09_radioterapia_post_NAC/RESUMEN_03_radioterapia_post_NAC.md) — *?* · 

## 10 — Pronóstico y supervivencia

- **2025** · [Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer](10_pronostico_supervivencia/2025_Perry_Predictors-pCR-chemo-IO_Ann-Surg-Oncol.md) — *Lauren M Perry* · PMID 40025324 · PMC12055475 · [DOI](https://doi.org/10.1245/s10434-025-17081-7)
- **2024** · [Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.](10_pronostico_supervivencia/2024_Dalton_HER2-NAC-axillary_AnnSurgOnco.md) — *Dalton JC* · PMID 39014162 · PMC11452275 · [DOI](https://doi.org/10.1245/s10434-024-15812-w)
- **2024** · [Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival](10_pronostico_supervivencia/2024_Houvenaeghel_pCR-prognosis_Cancer-Med.md) — *Gilles Houvenaeghel* · PMID 38327130 · PMC10904968 · [DOI](https://doi.org/10.1002/cam4.6930)
- **2022** · [Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67](10_pronostico_supervivencia/2022_Boughey_Luminal-Ki67-nodal-pCR_Ann-Surg-Oncol.md) — *Judy C Boughey* · PMID 35569077 · PMC9466990 · [DOI](https://doi.org/10.1245/s10434-022-11871-z)
- **2020** · [Tumor-infiltrating lymphocytes benefit prediction of axillary pathologic response and prognostication of event-free survival in HER2-positive and biopsy-proven node-positive breast cancer treated with](10_pronostico_supervivencia/2020_Liu_HER2-NAC-axillary_BreaCancRes.md) — *Liu S* · PMID 33165709 · [DOI](https://doi.org/10.1007/s10549-020-06015-4)
- **2020** · [Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on p](10_pronostico_supervivencia/2020_Omranipour_HER2-NAC-axillary_EurJBrea.md) — *Omranipour R* · PMID 32656523 · PMC7337920 · [DOI](https://doi.org/10.5152/ejbh.2020.5487)
- **----** · [Resumen ejecutivo — Predictores de respuesta nodal a NAC: ¿quién convertirá a ypN0?](10_pronostico_supervivencia/RESUMEN_05_predictores_ypN0.md) — *?* · 

## _amstar2_toolkit

- **2026** · [Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.](_amstar2_toolkit/sr_corpus_augmented/2026_Abdulla_Meta-analisis_Ann-Surg-Oncol.md) — *Abdulla Hussain A* · PMID 41545613 · [DOI](https://doi.org/10.1245/s10434-025-19070-2)
- **2025** · [Use of superparamagnetic iron oxide for sentinel lymph node detection following neoadjuvant systemic therapy. A systematic review and meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2025_Boland_Meta-analisis_Eur-J-Surg-Oncol.md) — *Boland M R* · PMID 40009931 · [DOI](https://doi.org/10.1016/j.ejso.2025.109684)
- **2025** · [Impact of postmastectomy radiotherapy on locoregional recurrence and survival in patients with ypN0 breast cancer after neoadjuvant chemotherapy: A comprehensive meta-analysis and systematic review.](_amstar2_toolkit/sr_corpus_augmented/2025_Ding_Meta-analisis_J-Cancer-Res-Ther.md) — *Ding Fangjie* · PMID 40317154 · [DOI](https://doi.org/10.4103/jcrt.jcrt_1279_24)
- **2025** · [Different strategies in de-escalation of axillary surgery in node-positive breast cancer following neoadjuvant treatment: a systematic review and meta-analysis of long-term outcomes.](_amstar2_toolkit/sr_corpus_augmented/2025_Man_Meta-analisis_Breast-Cancer.md) — *Man Vivian* · PMID 40186790 · PMC12174186 · [DOI](https://doi.org/10.1007/s12282-025-01692-9)
- **2025** · [Long-Term Survival of Node-Positive Breast Cancer with Complete Nodal Response to Neoadjuvant Chemotherapy Treated with Sentinel Lymph Node Biopsy Alone: A Meta-Analysis.](_amstar2_toolkit/sr_corpus_augmented/2025_Wang_Meta-analisis_Oncology.md) — *Wang Zhanwei* · PMID 39899993 · [DOI](https://doi.org/10.1159/000543662)
- **2024** · [Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement](_amstar2_toolkit/sr_corpus_augmented/2024_deWild_TAD-systematic-review_BJS.md) — *Sabine R de Wild* · PMID 38531689 · PMC10965400 · [DOI](https://doi.org/10.1093/bjs/znae071)
- **2024** · [Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2- Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis](_amstar2_toolkit/sr_corpus_augmented/2024_Vasigh_NET-vs-NAC-cN-positive_Breast-J.md) — *Mahtab Vasigh* · PMID 39742366 · PMC11315960 · [DOI](https://doi.org/10.1155/2024/8866756)
- **2023** · [Axillary staging in node-positive breast cancer converting to node negativity through neoadjuvant chemotherapy: Current evidence and perspectives](_amstar2_toolkit/sr_corpus_augmented/2023_Banys-Paluchowski_Axillary-staging-cN-to-ycN0_Scand-J-Surg.md) — *Maggie Banys-Paluchowski* · PMID 36642957 · [DOI](https://doi.org/10.1177/14574969221145892)
- **2023** · [The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2023_Ma_Meta-analisis_Front-Oncol.md) — *Ma Le* · PMID 37064127 · PMC10090490 · [DOI](https://doi.org/10.3389/fonc.2023.1167912)
- **2023** · [Evolution and refinement of magnetically guided sentinel lymph node detection in breast cancer: meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2023_Pantiora_Meta-analisis_Br-J-Surg.md) — *Pantiora Eirini* · PMID 36560842 · PMC10364535 · [DOI](https://doi.org/10.1093/bjs/znac426)
- **2022** · [Breast surgery after neoadjuvant therapy](_amstar2_toolkit/sr_corpus_augmented/2022_Gnant_Breast-surgery-after-NAT_Curr-Opin-Oncol.md) — *Michael Gnant* · PMID 36083127 · [DOI](https://doi.org/10.1097/CCO.0000000000000906)
- **2022** · [Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data.](_amstar2_toolkit/sr_corpus_augmented/2022_Lin_Meta-analisis_Ann-Surg-Oncol.md) — *Lin Shi-Qian* · PMID 35018590 · [DOI](https://doi.org/10.1245/s10434-021-11297-z)
- **2022** · [Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2022_Song_Meta-analisis_Cancer-Med.md) — *Song Yu-Xin* · PMID 35502768 · PMC9678111 · [DOI](https://doi.org/10.1002/cam4.4769)
- **2022** · [The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review.](_amstar2_toolkit/sr_corpus_augmented/2022_Vxe1zquez_Revision-sistematica_Clin-Transl-Oncol.md) — *V&#xe1;zquez Juan C* · PMID 36153763 · [DOI](https://doi.org/10.1007/s12094-022-02953-1)
- **2021** · [Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,5](_amstar2_toolkit/sr_corpus_augmented/2021_Cao_Meta-analisis_Breast.md) — *Cao Siyang* · PMID 34325383 · PMC8334738 · [DOI](https://doi.org/10.1016/j.breast.2021.07.015)
- **2021** · [Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis](_amstar2_toolkit/sr_corpus_augmented/2021_Samiei_Axillary-pCR-by-subtype_JAMA-Surg.md) — *Sanaz Samiei* · PMID 33881478 · PMC8060891 · [DOI](https://doi.org/10.1001/jamasurg.2021.0891)
- **2019** · [Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2019_Simons_Meta-analisis_Ann-Surg.md) — *Simons Janine M* · PMID 30312200 · PMC6369968 · [DOI](https://doi.org/10.1097/SLA.0000000000003075)
- **2018** · [Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review.](_amstar2_toolkit/sr_corpus_augmented/2018_Krug_Revision-sistematica_Strahlenther-Onkol.md) — *Krug David* · PMID 29383405 · [DOI](https://doi.org/10.1007/s00066-018-1270-x)
- **2018** · [Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer.](_amstar2_toolkit/sr_corpus_augmented/2018_Tee_Meta-analisis_Br-J-Surg.md) — *Tee S R* · PMID 30311642 · [DOI](https://doi.org/10.1002/bjs.10986)
- **2016** · [Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis i](_amstar2_toolkit/sr_corpus_augmented/2016_El-Hage-Chehade_Meta-analisis_Am-J-Surg.md) — *El Hage Chehade Hiba* · PMID 27671032 · [DOI](https://doi.org/10.1016/j.amjsurg.2016.07.018)
- **2016** · [The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.](_amstar2_toolkit/sr_corpus_augmented/2016_Geng_Meta-analisis_PLoS-One.md) — *Geng Chong* · PMID 27606623 · PMC5015960 · [DOI](https://doi.org/10.1371/journal.pone.0162605)
- **2015** · [Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2015_Mocellin_Meta-analisis_Int-J-Cancer.md) — *Mocellin Simone* · PMID 26084763 · [DOI](https://doi.org/10.1002/ijc.29644)
- **2015** · [The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2015_van-Nijnatten_Meta-analisis_Eur-J-Surg-Oncol.md) — *van Nijnatten T J A* · PMID 26329781 · [DOI](https://doi.org/10.1016/j.ejso.2015.07.020)
- **2014** · [Sentinel lymph node in oesophageal cancer-a systematic review and meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2014_Nagaraja_Meta-analisis_J-Gastrointest-Oncol.md) — *Nagaraja Vinayak* · PMID 24772341 · PMC3999634 · [DOI](https://doi.org/10.3978/j.issn.2078-6891.2014.008)
- **2014** · [Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.](_amstar2_toolkit/sr_corpus_augmented/2014_Schipper_Revision-sistematica_Eur-J-Radiol.md) — *Schipper R J* · PMID 25458227 · [DOI](https://doi.org/10.1016/j.ejrad.2014.09.020)
- **2012** · [Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.](_amstar2_toolkit/sr_corpus_augmented/2012_Mamounas_Radioterapia-NAC_J-Clin-Oncol.md) — *Mamounas Eleftherios P* · PMID 23032615 · PMC3488269 · [DOI](https://doi.org/10.1200/JCO.2011.40.8369)
- **2012** · [Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer.](_amstar2_toolkit/sr_corpus_augmented/2012_Moody_Meta-analisis_Surgery.md) — *Moody Lisa C* · PMID 22938899 · [DOI](https://doi.org/10.1016/j.surg.2012.06.017)
- **2011** · [The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2011_Tan_Meta-analisis_J-Surg-Oncol.md) — *Tan Veronique K M* · PMID 21456092 · [DOI](https://doi.org/10.1002/jso.21911)
- **2009** · [Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis.](_amstar2_toolkit/sr_corpus_augmented/2009_Kelly_Revision-sistematica_Acad-Radiol.md) — *Kelly Aine M* · PMID 19345896 · [DOI](https://doi.org/10.1016/j.acra.2009.01.026)
- **2009** · [Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review.](_amstar2_toolkit/sr_corpus_augmented/2009_van-Deurzen_Revision-sistematica_Eur-J-Cancer.md) — *van Deurzen Carolien H M* · PMID 19716287 · [DOI](https://doi.org/10.1016/j.ejca.2009.08.001)
- **2006** · [Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.](_amstar2_toolkit/sr_corpus_augmented/2006_Xing_Meta-analisis_Br-J-Surg.md) — *Xing Y* · PMID 16329089 · [DOI](https://doi.org/10.1002/bjs.5209)
- **----** · [CLAUDE.md](_amstar2_toolkit/CLAUDE.md) — *?* · 
- **----** · [Cohen's κ — inter-rater agreement (3 raters: LLM Opus 4.7, Sergio, David)](_amstar2_toolkit/peer_review/consensus/cohens_kappa.md) — *?* · 
- **----** · [AMSTAR-2 3-rater peer review consensus](_amstar2_toolkit/peer_review/consensus/consensus_summary.md) — *?* · 
- **----** · [The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis](_amstar2_toolkit/sr_corpus_augmented/2021_Swarnkar_MLNB-TAD-pooled_Cancers.md) — *Parinita K Swarnkar* · PMID 33810544 · PMC8037051 · [DOI](https://doi.org/10.3390/cancers13071539)
- **----** · [The Feasibility and Reliability of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Negative Axillary Lymph Nodes-A Meta-analysis.](_amstar2_toolkit/sr_corpus_augmented/2024_Yu_Meta-analisis_Breast-Cancer-Auckl.md) — *Yu Mengjie* · PMID 38826850 · PMC11141228 · [DOI](https://doi.org/10.1177/11782234241255856)

## _excluded_after_triage_2026-05-14

- **2023** · [Axillary staging in node-positive breast cancer converting to node negativity through neoadjuvant chemotherapy: Current evidence and perspectives](_excluded_after_triage_2026-05-14/2023_Banys-Paluchowski_Axillary-staging-cN-to-ycN0_Scand-J-Surg.md) — *Maggie Banys-Paluchowski* · PMID 36642957 · [DOI](https://doi.org/10.1177/14574969221145892)
- **2023** · [The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis.](_excluded_after_triage_2026-05-14/2023_Ma_Meta-analisis_Front-Oncol.md) — *Ma Le* · PMID 37064127 · PMC10090490 · [DOI](https://doi.org/10.3389/fonc.2023.1167912)
- **2023** · [Evolution and refinement of magnetically guided sentinel lymph node detection in breast cancer: meta-analysis.](_excluded_after_triage_2026-05-14/2023_Pantiora_Meta-analisis_Br-J-Surg.md) — *Pantiora Eirini* · PMID 36560842 · PMC10364535 · [DOI](https://doi.org/10.1093/bjs/znac426)
- **2022** · [Breast surgery after neoadjuvant therapy](_excluded_after_triage_2026-05-14/2022_Gnant_Breast-surgery-after-NAT_Curr-Opin-Oncol.md) — *Michael Gnant* · PMID 36083127 · [DOI](https://doi.org/10.1097/CCO.0000000000000906)
- **2016** · [The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis.](_excluded_after_triage_2026-05-14/2016_Geng_Meta-analisis_PLoS-One.md) — *Geng Chong* · PMID 27606623 · PMC5015960 · [DOI](https://doi.org/10.1371/journal.pone.0162605)
- **2014** · [Sentinel lymph node in oesophageal cancer-a systematic review and meta-analysis.](_excluded_after_triage_2026-05-14/2014_Nagaraja_Meta-analisis_J-Gastrointest-Oncol.md) — *Nagaraja Vinayak* · PMID 24772341 · PMC3999634 · [DOI](https://doi.org/10.3978/j.issn.2078-6891.2014.008)
- **2012** · [Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.](_excluded_after_triage_2026-05-14/2012_Mamounas_Radioterapia-NAC_J-Clin-Oncol.md) — *Mamounas Eleftherios P* · PMID 23032615 · PMC3488269 · [DOI](https://doi.org/10.1200/JCO.2011.40.8369)
- **2012** · [Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer.](_excluded_after_triage_2026-05-14/2012_Moody_Meta-analisis_Surgery.md) — *Moody Lisa C* · PMID 22938899 · [DOI](https://doi.org/10.1016/j.surg.2012.06.017)
- **2011** · [The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis.](_excluded_after_triage_2026-05-14/2011_Tan_Meta-analisis_J-Surg-Oncol.md) — *Tan Veronique K M* · PMID 21456092 · [DOI](https://doi.org/10.1002/jso.21911)
- **----** · [The Feasibility and Reliability of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Negative Axillary Lymph Nodes-A Meta-analysis.](_excluded_after_triage_2026-05-14/2024_Yu_Meta-analisis_Breast-Cancer-Auckl.md) — *Yu Mengjie* · PMID 38826850 · PMC11141228 · [DOI](https://doi.org/10.1177/11782234241255856)

## predictor_ypN0

- **----** · [Data dictionary - ypN0 clinical predictor datasets](predictor_ypN0/data/predictor_data_dictionary.md) — *?* · 
- **----** · [Casos clínicos resueltos](predictor_ypN0/docs/casos_clinicos_uso.md) — *?* · 
- **----** · [Comparación de niveles: Nivel 1 vs Nivel 2 vs Nivel 3 (futuro)](predictor_ypN0/docs/comparacion_niveles.md) — *?* · 
- **----** · [Limitaciones e interpretación crítica](predictor_ypN0/docs/limitaciones.md) — *?* · 
- **----** · [Manual clínico - Predictor ypN0 tras NAC](predictor_ypN0/docs/manual_clinico.md) — *?* · 
- **----** · [Nivel 2 - Meta-regresion y nomograma para prediccion de ypN0 tras NAST](predictor_ypN0/nivel2_metaregresion/results.md) — *?* · 
- **----** · [PROSPERO Protocol — Umbrella Review](predictor_ypN0/paper_umbrella/01_protocolo/PROSPERO_protocol.md) — *?* · 
- **----** · [Pilot Search Strategy](predictor_ypN0/paper_umbrella/01_protocolo/search_strategy_pilot.md) — *?* · 
- **----** · [AMSTAR-2 detailed report — full-text LLM-assisted scoring (Opus 4.7)](predictor_ypN0/paper_umbrella/02_amstar2/amstar2_detailed.md) — *?* · 
- **----** · [Data extraction — filled (33 included SRs/MAs)](predictor_ypN0/paper_umbrella/03_prisma/data_extraction_filled.md) — *?* · PMID 16329089 · [DOI](https://doi.org/10.1002/bjs.5209)
- **----** · [Data extraction template — one form per included SR/MA](predictor_ypN0/paper_umbrella/03_prisma/data_extraction_template.md) — *?* · 
- **----** · [PRISMA 2020 Flow — Data file](predictor_ypN0/paper_umbrella/03_prisma/prisma_flow_data.md) — *?* · 
- **----** · [Structured Abstract](predictor_ypN0/paper_umbrella/04_manuscrito/abstract.md) — *?* · 
- **----** · [GRADE Certainty-of-Evidence Assessment](predictor_ypN0/paper_umbrella/04_manuscrito/grade_assessment.md) — *?* · 
- **----** · [Methods — Certainty of evidence (paragraph for insertion)](predictor_ypN0/paper_umbrella/04_manuscrito/grade_methods_paragraph.md) — *?* · 
- **----** · [Table 6 — Summary of Findings (condensed for Results section)](predictor_ypN0/paper_umbrella/04_manuscrito/grade_table_for_results.md) — *?* · 
- **----** · [Highlights (Elsevier style)](predictor_ypN0/paper_umbrella/04_manuscrito/highlights.md) — *?* · 
- **----** · [Axillary Management After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: An Umbrella Review of 23 Systematic Reviews and Meta-Analyses (2006-2026)](predictor_ypN0/paper_umbrella/04_manuscrito/manuscript.md) — *?* · 
- **----** · [References](predictor_ypN0/paper_umbrella/04_manuscrito/references.md) — *?* · 
- **----** · [Table 1. Characteristics of the 33 originally included systematic reviews and meta-analyses (2006-2026), with PICOS eligibility verdict](predictor_ypN0/paper_umbrella/04_manuscrito/tables/table1_included_SRs.md) — *?* · 
- **----** · [Table 1A. Systematic reviews and meta-analyses fully ELIGIBLE for primary synthesis (n=13)](predictor_ypN0/paper_umbrella/04_manuscrito/tables/table1A_included_SRs_ELIGIBLE.md) — *?* · 
- **----** · [Table 1B. Systematic reviews retained for SENSITIVITY ANALYSIS (n=10) — population-mixed cN0+cN+, intervention-adjacent (imaging/RT/NET), or other minor PICOS deviations](predictor_ypN0/paper_umbrella/04_manuscrito/tables/table1B_borderline_SRs.md) — *?* · 
- **----** · [Table 2. AMSTAR-2 detailed scoring of the 5 anchor systematic reviews — full-text LLM-augmented scoring](predictor_ypN0/paper_umbrella/04_manuscrito/tables/table2_amstar2_summary.md) — *?* · 
- **----** · [Table 3. Axillary pathologic complete response (ypN0) rates after neoadjuvant chemotherapy, by molecular subtype](predictor_ypN0/paper_umbrella/04_manuscrito/tables/table3_pCR_by_subtype.md) — *?* · 
- **----** · [Table 4. False-negative rate (FNR) of axillary techniques after neoadjuvant chemotherapy in cN+ disease](predictor_ypN0/paper_umbrella/04_manuscrito/tables/table4_FNR_by_technique.md) — *?* · 
- **----** · [Table 5. Synthesis of international clinical practice guidelines on omission of completion axillary lymph node dissection (ALND) in cN+ patients converting to ypN0 after neoadjuvant chemotherapy](predictor_ypN0/paper_umbrella/04_manuscrito/tables/table5_guideline_synthesis.md) — *?* · 
- **----** · [Figure legends](predictor_ypN0/paper_umbrella/05_figuras/legends.md) — *?* · 
- **----** · [Cohen's κ — inter-rater agreement (3 raters: LLM Opus 4.7, Sergio, David)](predictor_ypN0/paper_umbrella/06_supplementary/peer_review_audit/cohens_kappa.md) — *?* · 
- **----** · [AMSTAR-2 3-rater peer review consensus](predictor_ypN0/paper_umbrella/06_supplementary/peer_review_audit/consensus_summary.md) — *?* · 
- **----** · [Supplementary Material S1 — Complete Search Strategy](predictor_ypN0/paper_umbrella/06_supplementary/S1_search_strategy.md) — *?* · 
- **----** · [Supplementary Material S2 — PRISMA 2020 Checklist](predictor_ypN0/paper_umbrella/06_supplementary/S2_PRISMA_2020_checklist.md) — *?* · 
- **----** · [Supplementary Material S3 — AMSTAR-2 Full Quality Assessment](predictor_ypN0/paper_umbrella/06_supplementary/S3_AMSTAR2_full.md) — *?* · 
- **----** · [Supplementary Material S4 — Excluded Studies with Reasons](predictor_ypN0/paper_umbrella/06_supplementary/S4_excluded_studies.md) — *?* · 
- **----** · [Supplementary Material S5 — Extended Data Extraction Table](predictor_ypN0/paper_umbrella/06_supplementary/S5_data_extraction_extended.md) — *?* · 
- **----** · [Supplementary Material S6 — Glossary of Abbreviations and Definitions](predictor_ypN0/paper_umbrella/06_supplementary/S6_glossary.md) — *?* · 
- **----** · [Supplementary Material S7 — GRADE Summary of Findings (SoF) Table](predictor_ypN0/paper_umbrella/06_supplementary/S7_GRADE_summary_of_findings.md) — *?* · 
- **----** · [Cohen's κ — inter-rater agreement (3 raters: LLM Opus 4.7, Sergio, David)](predictor_ypN0/paper_umbrella/06_supplementary/S8_three_rater_kappa.md) — *?* · 
- **----** · [AMSTAR-2 3-rater peer review consensus](predictor_ypN0/paper_umbrella/06_supplementary/S8b_consensus_summary.md) — *?* · 
- **----** · [Final Structured Abstract — Three Length Variants](predictor_ypN0/paper_umbrella/07_submission/abstract_for_journal_submission.md) — *?* · 
- **----** · [Cover Letter — British Journal of Surgery (BJS)](predictor_ypN0/paper_umbrella/07_submission/cover_letter_BJS.md) — *?* · 
- **----** · [Cover Letter — European Journal of Surgical Oncology (EJSO)](predictor_ypN0/paper_umbrella/07_submission/cover_letter_EJSO.md) — *?* · 
- **----** · [Cover Letter — The Breast (EUSOMA / EUSOBI / European Society of Breast Cancer Specialists)](predictor_ypN0/paper_umbrella/07_submission/cover_letter_TheBreast.md) — *?* · 
- **----** · [CRediT Contributor Roles Taxonomy Statement](predictor_ypN0/paper_umbrella/07_submission/CRediT_statement.md) — *?* · 
- **----** · [Data Availability Statement](predictor_ypN0/paper_umbrella/07_submission/data_availability.md) — *?* · 
- **----** · [Title Page](predictor_ypN0/paper_umbrella/07_submission/title_page.md) — *?* · 
- **----** · [Guia de despliegue en Vercel](predictor_ypN0/site/DEPLOY.md) — *?* · 
- **----** · [Calibration report - Nivel 1 ypN0 predictor](predictor_ypN0/tests/calibration_report.md) — *?* · 
- **----** · [Test results - Nivel 1 ypN0 predictor](predictor_ypN0/tests/test_results.md) — *?* · 
